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Abstract
Excess lipid induced metabolic disorders are one of the major existing challenges for the society. Among many 
different causes of lipid disorders, overproduction and compromised catabolism of triacylglycerol-rich very low density 
lipoproteins (VLDL) have become increasingly prevalent leading to hyperlipidemia worldwide. This review provides the 
latest understanding in different aspects of VLDL assembly process, including structure-function relationships within 
apoB, mutations in APOB causing hypobetalipoproteinemia, significance of modulating microsomal triglyceride-
transfer protein activity in VLDL assembly, alterations of VLDL assembly by different fatty acid species, and hepatic 
proteins involved in vesicular trafficking, and cytosolic lipid droplet metabolism that contribute to VLDL assembly. The 
role of lipoprotein receptors and exchangeable apolipoproteins that promote or diminish VLDL assembly and secretion 
is discussed. New understanding on dysregulated insulin signaling as a consequence of excessive triacylglycerol-rich 
VLDL in the plasma is also presented. It is hoped that a comprehensive view of protein and lipid factors that contribute 
to molecular and cellular events associated with VLDL assembly and secretion will assist in the identification of 
pharmaceutical targets to reduce disease complications related to hyperlipidemia.
Introduction
Lipids of dietary origin as well as those stored in the adi-
pose tissues act as energy sources for mammalian cells.
Since lipids are hydrophobic in nature, mammals have
evolved a mechanism such that the insoluble lipids are
made soluble in the form of lipoproteins for transporta-
tion and delivery to various organs and tissues by the cir-
culatory system. Formation and secretion of lipoprotein
particles is primarily achieved in the liver (as VLDL) and
in the intestine (as chylomicrons). The process involved
in the assembly and secretion of hepatic VLDL or intesti-
nal chylomicrons is complex and has been studied exten-
sively for the past 2-3 decades. Lipid and protein factors
that affect various steps during the assembly and secre-
tion of VLDL and chylomicrons have been identified. The
assembly process of hepatic VLDL is initiated in the
endoplasmic reticulum (ER) as soon as apoB-100 is trans-
lated and translocated into the lumenal side where the
elongating apoB-100 polypeptide chain recruits various
lipids co-translationally. Each VLDL is composed of one
molecule of apoB-100, multiple copies of other apolipo-
proteins, together with varied amounts of triacylglycerol
(TAG) and cholesteryl esters, depending upon the size of
resulting particles. Cellular and molecular mechanisms
by which different lipid and protein components are
brought together for VLDL assembly are not fully under-
stood and remain to be defined. A protein factor other
than apoB that is absolutely required for VLDL assembly
is the microsomal triglyceride-transfer protein (MTP).
The obligatory role of MTP in VLDL assembly/secretion
is exemplified by human familial abetalipoproteinemia,
characterized by nearly a complete absence of apoB-con-
taining lipoproteins including VLDL (and chylomicrons
as well). Available evidence indicates that among different
lipid and protein constituents of VLDL, the availability of
functional apoB-100 and TAG are by far the most critical
for the assembly of secretion-competent VLDL within
the ER lumen. An array of protein factors involved in
secretory protein translation and translocation across the
ER membrane are responsible for initial apoB-100 folding
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to attain lipid-binding capability within the microsomal
lumen. Pathological conditions that disfavor apoB-100
folding or binding of lipids to apoB will result in aborted
VLDL assembly and premature intracellular degradation
of apoB-100 during or after translation.
Structural and functional elements within apoB-
100
The human APOB gene, located on the distal end of the
short arm of chromosome 2 (2p23-2p24), encodes a ~20
kb mRNA that is translated into the full-length apoB-100
consisting of 4,536 amino acids in the liver [1-3]. A trun-
cated form of apoB, known as apoB-48, represents the N-
terminal 48% of apoB-100 and is produced in the intes-
tine by an mRNA editing mechanism [4]. In humans,
apoB-100 and apoB-48 are obligatory proteins for the
assembly of respective hepatic VLDL and intestinal chy-
lomicrons [5]. In mouse and rat, the liver synthesizes
apoB-48 in addition to apoB-100 [6]. Because of their
enormous size, extreme hydrophobicity along with varied
extents in lipid-binding, the 3-D structure of apoB-100 or
apoB-48 has not been solved at the atomic level. How-
ever, attempts have been made, using various algorithms,
to compute the structures of various domains of apoB-
100. The modeled human apoB-100 molecule is com-
posed of five domains enriched with alternating amphip-
athic α-helices and amphipathic β-strands, designated
βα1-β1-α2-β2-α3 [7]. Various domains and their approxi-
mate locations in apoB-100 are depicted in Fig. 1A.
Moreover, based on the homology to lamprey lipovitellin,
a modeled structure for the N-terminal ~930 amino acids
of human apoB-100 has been proposed [8,9]. This model
predicts a βα1 domain structure consisting of β-barrel
(the first 264 residues) and α-helical bundle (residues
292-593), followed by two amphipathic β-sheets termed
C sheet (residues 611-782) and A sheet (residues 783-
930), respectively, that may form a lipid-binding pocket
[10]. Scanning transmission electron microscopy studies
have provided direct evidence that nanogold-labeled
apoB fragment (apoB6.4-17) interacted with lipids [11]. A
model of human apoB-100 associated with low density
lipoprotein (LDL) has been obtained using images cap-
tured by electron cryomicroscopy, in which a single
apoB-100 molecule with its α-helix and β-sheet rich
domains across the LDL surface is proposed [12].
The N-terminal region of apoB contains several bind-
ing sites for MTP, an apoB-specific molecular chaperone
essential for apoB-100 to fold properly during VLDL
assembly/secretion [13,14]. Multiple MTP-binding sites
have been identified within the N-terminal βα1 domain
of apoB [13,15,16], and the affinity of MTP-binding is
inversely related to the apoB polypeptide length [17].
Apart from binding to MTP, the βα1 domain of apoB-100
also binds to scavenger receptors in human macrophages
[18] and to lipoprotein lipase [19]. The β1 domain (amino
acids 827-1880) of apoB-100 is predominantly made of
amphipathic β strands and is involved in irreversible
lipid-binding [20,21]. The β2 domain located at the C-ter-
minal half of apoB-100 possesses LDL receptor-binding
property [22,23]. The role of the intervening amphipathic
α - h e l i x  e n r i c h e d  d o m a i n  α 2  a n d  t h e  C -t e r m i n a l  α 3  o f
apoB-100 may represent a flexible region that imparts
elasticity to the molecule allowing recruitment of various
amounts of core lipids [24].
The amino acid sequences within apoB-100 essential
for lipoprotein assembly and secretion have been investi-
gated extensively using two approaches, namely trunca-
tion mutagenesis and chimeric protein expression
analysis. Incremental truncation of human apoB polypep-
tide from the carboxyl terminus successively decreased
its ability to form buoyant lipoprotein particles [25,26].
Under lipid rich conditions, the ability of apoB to assem-
ble VLDL resides at the length transition between the N-
terminal ~30% and ~40% of the polypeptide, a region
enriched with amphipathic β strands (i.e. the β1 domain)
[26]. Studies with chimera proteins, in which segments of
apoB derived from the β1 domain were fused with apoA-
I, have shown that inclusion of the amphipathic β strands
conferred the ability to assemble VLDL [26]. The amino
acid sequences within the β1 domain also influence the
rate of apoB translocation across the ER membrane and
its susceptibility to proteasomal degradation [27] (for
apoB degradation, see below). These studies suggest that
the amino acid sequences within the β1 domain are
important for lipid-binding in the VLDL assembly pro-
cess.
Human apoB-100 undergoes several posttranslational
modifications, including disulfide bond formation, N-
linked glycosylation, and palmitoylation. Mutational
analysis has shown that among six disulfide linkages
within the βα1 domain, the two involving Cys51/Cys70 and
Cys218/Cys234 are essential for apoB-lipoprotein assembly
and secretion [28,29]. Results from the cysteine mutagen-
esis studies corroborate with data obtained from dithio-
threitol treatment experiment in which abolishing apoB
disulfide bond formation with the reducing agent
resulted in decreased apoB secretion [30].
There are 20 potential N-linked glycosylation sites
within human apoB-100, of which 16 Asn residues are
conjugated with oligosaccharides in apoB-100 associated
with plasma LDL [31]. The requirement of Asn158, Asn956,
Asn1341, Asn1350, and Asn1496 residues within the amino
terminus of apoB-100 has been determined by mutagene-
sis experiments; results from these studies suggested that
the loss of N-glycans, particularly at Asn1496, resulted in
decreased stability of apoB and reduced secretion of
TAG-rich lipoproteins [32]. Thus, in addition to lipid
binding sequences of apoB, the N-linked oligosaccharidesSundaram and Yao Nutrition & Metabolism 2010, 7:35
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conjugated to apoB also play a role conferring the post-
translational stability and the ability to assemble lipopro-
teins.
Palmitoylation of human apoB is observed in plasma
LDL [33] as well as apoB found in cultured hepatic cell
lines [34,35]. The 16-carbon fatty acid palmitate is cova-
lently linked to cysteine residues via thioester bonds.
Mutagenesis studies of the four cysteine residues Cys1085,
Cys1396, Cys1478, and Cys1635 suggest that the lack of palm-
itoylation within the N-terminal region of apoB does not
compromise the ability of apoB-48 to assemble lipopro-
teins [36]. However, decreased secretion of the short
truncation mutant apoB-29 was observed as a result of
lack of palmitoylation [35]. It is likely that an interplay
exists between the length of amphipathic lipid-binding
sequences and palmitoylation of apoB that regulate TAG-
rich lipoprotein assembly and secretion.
Many mutations in the APOB gene have been charac-
terized and found to affect the plasma concentrations of
apoB, TAG and cholesterol. The most characterized
APOB mutations are the ones found in familial hypobeta-
lipoproteinemia (FHBL) [37]. FHBL is inherited in a
Mendelian fashion as an autosomal dominant trait.
Heterozygote FHBL individuals invariably have plasma
cholesterol, TAG, LDL-cholesterol, and apoB at levels
approximately 1/3 of normal, whereas homozygote FHBL
subjects have barely detectable levels of apoB. Individuals
with FHBL have reduced risk of cardiovascular diseases
presumably owing to low plasma apoB and cholesterol
concentrations [38]. Various truncated forms of apoB,
such as apoB-32 [39], apoB-55 [40], apoB-61 [41], apoB-
75 [42], and apoB-83 [43] to name a few, are found in
human subjects displaying FHBL phenotype as a result of
nonsense mutations occurring throughout the apoB poly-
Figure 1 Model of the N-terminal of apoB and positions of FHBL mutations. A, schematic diagram of apoB-100, with predicted locations of βα1, 
β1, α2, β2, and α3 domains are shown on the top. B, positions of non-truncating FHBL mutations within the N-terminal 1,000 amino acids of apoB-100. 
Mutations associated with phenotype of hypobetalipoproteinemia (hypoβ) are shown on the top, whereas mutations associated with phenotype of 
both hypoβ and hepatic steatosis are shown below. C, proposed homologous model of the N-terminal ~930 amino acids of apoB. The β-barrel, α-
helical, and β sheet (C-sheet and A-sheet) are highlighted in green, cyan, red, and blue, respectively. Locations of Ala31, Gly275, Leu324, Leu343, Arg463, and 
Gly912 within the modeled βα1 domain are shown as yellow spheres.Sundaram and Yao Nutrition & Metabolism 2010, 7:35
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peptide. To date, novel truncating mutations within
APOB are continually being identified in FBHL patients
devoid of cardiovascular diseases [44]. Cell culture and
transgenic mouse studies with a variety of truncated apoB
forms (ranging from apoB-15 to apoB-94) showed that
most of the C-terminally truncated apoBs were secreted
as efficiently as normal apoB-100 or apoB-48
[25,26,45,46].
Non-truncating mutations in APOB also cause FHBL;
most of these nonsynoymous mutations occur within the
βα1 domain of apoB [47-49]. Biochemical analysis has
shown that unlike the apoB truncation mutants whose
secretion efficiency was normal, the nonsynoymous apoB
mutants exhibited markedly decreased secretion from
transfected cells and abnormal retention of the mutant
proteins within the ER or Golgi [49,50]. Twelve non-trun-
cating mutations within the N-terminal 1,000 amino
acids of apoB-100, some of them associated with hypo-
betalipoproteinemia and some confounded with hepatic
steatosis, are shown in Fig. 1B. Table 1 summarizes the
seven non-truncating apoB mutations that have been bio-
chemically characterized. For example, the mutant A31P
apoB proteins identified in an Italian FHBL subject
showed severely impaired secretion and augmented
intracellular degradation by proteasomes and autophagy
[50]. The identification of missense mutations within the
βα1 domain of apoB indicates the structural and func-
tional importance of this domain, and also provides addi-
tional explanation for the early observations that
recombinant apoB segments lacking the N-terminal
1,000 amino acids were either secreted poorly or not
secreted at all [25,26]. Position of the amino acids corre-
sponding to FHBL mutations within the predicted βα1
domain of apoB is depicted in Fig. 1C.
MTP and VLDL assembly
MTP is a heterodimer consisting of a 97-kDa lipid-bind-
ing and -transfer subunit [51] and a 55-kDa protein disul-
fide isomerase (PDI) [52] that is not required for lipid-
transfer activity [53]. MTP is predominantly expressed in
the hepatocytes and enterocytes where it transfers neu-
tral lipids required for the assembly of apoB containing
lipoproteins such as VLDL in the liver and chylomicrons
in the intestine. Mutations leading to loss of MTP activity
is linked to familial abetalipoproteinemia [54] in which
the affected individuals have undetectable levels of apoB
in the plasma. Structural studies of various domains
within MTP have revealed a lipid-binding cavity resem-
bling those found in intracellular lipid-binding proteins.
The entrance of the cavity contains two conserved helices
(helix-A: amino acids 725-736 and helix-B: amino acids
781-786). Mutational analysis of the helices has shown
that helix A is required for the acquisition of lipids from
phospholipid membranes whereas helix B plays a role in
transferring lipids to the lipid-binding cavity. Mutations
introduced in either of the helices resulted in abolition of
lipid binding, which provides an explanation for abetali-
poproteinemia found in humans carrying point muta-
tions in the MTTP gene [55].
Availability of lipids in the vicinity of MTP is crucial for
proper acquisition and transfer of lipids to the site of
VLDL assembly within the ER. Lack of sufficient lipids
supply compromises VLDL assembly and maturation,
resulting in poorly lipidated apoB polypeptides that are
prone to co- or post-translational degradation [56]. Inhi-
bition of MTP with chemical inhibitor results in a similar
outcome leading to the failure of VLDL assembly [57].
Studies with rat hepatoma McA-RH7777 cells have sug-
gested that the early stage of lipid assembly initiated dur-
ing apoB translation and translocation is facilitated by the
MTP activity. However, during the later stage of VLDL
assembly where bulk TAG is incorporated, the activity of
MTP appears not essential [58]. This stage-dependent
feature of MTP activity during VLDL assembly has also
been observed in human hepatoblastoma HepG2 cells
[59] and for the assembly of VLDL by McA-RH7777 cells
transfected with recombinant human apoB-48 [60].
Graded inactivation of MTP with increasing doses of
Table 1: Biochemically characterized APOB missense mutations in FHBL
Mutation Predicted 
location
Hepatosteatosis Secretion Retention Reference
A31P β-barrel yes <5% normal Golgi [50]
G275S α-helix yes 60% normal n.d. [50]
L324M α-helix yes 50% normal n.d. [50]
L343V α-helix yes 50% normal ER [48]
R463W α-helix yes 50% normal ER [47]
G912D β-sheet yes nearly normal n.d. [50]
G945S β-sheet yes 50% normal n.d. [50]
n.d, not determinedSundaram and Yao Nutrition & Metabolism 2010, 7:35
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MTP inhibitor has revealed that the assembly and secre-
tion of TAG-rich VLDL1 (Sf > 100) and VLDL2 (Sf 20-100)
are more dependent on MTP activity than TAG-poor
particles such as intermediate density lipoproteins (IDL)
and LDL [57]. Moreover, the requirement of MTP activity
is more pronounced for apoB-100 than for apoB-48, thus
MTP inhibition effectively decreases apoB-100 and TAG
secretion but has little effect on secretion of lipid-poor
apoB-48 [61]. Lipid pulse-chase analysis carried out in rat
primary hepatocytes after MTP activity was inhibited
revealed delayed removal of TAG from the membranes of
ER and Golgi. Inactivation of MTP did not affect lipolysis
or subsequent re-esterification of TAG but the re-esteri-
fied TAG was not secreted as VLDL [62]. These cell cul-
ture studies suggest that MTP facilitates recruitment of
TAG from the ER/Golgi membranes during VLDL
assembly without affecting TAG biosynthesis.
In addition to cell culture studies, the role of MTP in
VLDL assembly and secretion has also been investigated
using genetically modified mice. The liver specific Mttp
knockout mice displayed a phenotype equivalent to the
human abetalipoproteinemia (i.e.  absence of plasma
apoB-100 and low levels of apoB-48) and were resistant to
hypercholesterolemia induced by high cholesterol diet
[63]. Ultrastructural analysis of liver specimen of the
Mttp knockout mice has revealed absence of lipid parti-
cles within the ER/Golgi lumen, whereas in wildtype con-
t r ol m ic e  t h e li pidic bodies  of  VLDL s ize  we r e  r eadi ly
observable [64]. These results raise the possibility that the
MTP activity is required for mobilization and partition-
ing of TAG substrates into the microsomal lumen for
VLDL assembly.
Regulation of MTP expression is achieved by multiple
factors that are closely related to fatty acid metabolism
and changes in MTP expression is invariably associated
with altered hepatic VLDL production. Studies with L35
cells, derived as a single cell clone from the rat hepatoma
FAO cells, have shown that the inability of these cells to
assemble or secrete VLDL resulted from co-repression of
MTP and L-FABP (liver fatty acid binding protein) by
chicken ovalbumin upstream promoter transcription fac-
tor II that occupied the DR1 promoter region of L-FABP
and Mttp. Under these conditions, although VLDL secre-
tion was blocked, the liver did not develop steatosis. In
parental FAO cells, the DR1 promoter region of L-FABP
and Mttp was occupied by peroxisome proliferator-acti-
vated receptor α (PPARα)-retinoid × receptor α (RXRα),
and the transcription of L-FABP and MTP were normal,
hence the assembly and secretion of VLDL was ensured
[65]. In the leptin-deficient obese ob/ob mice, hepatoste-
atosis and insulin resistance (partly as a result of excessive
fatty acid influx into the liver) were ameliorated by dele-
tion of an orphan receptor small heterodimer partner
(SHP) [66]. This study has revealed that SHP acts as a
repressor of MTP mRNA transcription by liver receptor
homolog-1 and therefore decreases MTP activity and
VLDL secretion in ob/ob mice [66]. The MTP expression
is also regulated by FoxO1, a transcription factor that
plays a role in muscle cell growth and differentiation [67].
Studies with HepG2 cells have suggested that FoxO1
could bind to Mttp promoter region and directly stimu-
late MTP expression. It was also noticed that insulin
treatment suppressed FoxO1 mediated MTP expression,
and the insulin effect could be abolished by deleting or
mutating the FoxO1 binding site within the Mttp pro-
moter [68]. In addition, MTP expression can also be acti-
vated by Foxa2 together with PPARγ coactivator β (PGC-
1β), resulting in increased VLDL secretion [69].
In summary, cell culture and transgenic mouse studies
indicate that alteration in MTP activity has a direct effect
on VLDL production. Attenuating MTP expression and/
or activity without eliciting hepatosteatosis has been a
long sought-after strategy in treating dyslipidemia related
to overproduction of VLDL.
Fatty acid substrates affecting VLDL assembly and 
secretion
TAG utilized for VLDL assembly and secretion originates
from multiple biosynthesis pathways. Fatty acyl chains
used for TAG synthesis can be derived from de novo syn-
thesis or from hydrolysis of existing TAG, presumably
catalyzed by triacylglycerol hydrolase in the liver [70].
These fatty acyl chains are also used for phospholipid bio-
synthesis. In addition, hydrolysis of existing phospholip-
ids associated with intracellular membranes [71,72] or
exogenous phospholipids associated with high density
lipoproteins (HDL) [73], also provides fatty acyl chains
for TAG synthesis and secretion.
Comparative analyses have shown that the chemical
nature of fatty acids, such as the acyl chain length and the
extent of unsaturation (i.e. the number and position of
double bonds) of acyl chains, have a profound impact on
VLDL assembly and secretion. For instance, studies with
chicken primary hepatocytes treated with different
medium-chain fatty acids have shown that octanoate
(8:0), decanoate (10:0), or dodecanoate (12:0) signifi-
cantly decreased VLDL-apoB secretion compared to
palmitate (16:0) [74]. The inhibitory effect of octanoate
(usually present in coconut and breast milk) on VLDL
was linked to suppression of apoB gene expression and
apoB100 protein synthesis without affecting intracellular
degradation of apoB [75].
Contrasting saturated fatty acids with mono- or poly-
unsaturated fatty acids has shown that certain fatty acid
species are preferentially utilized over others for VLDL
assembly and secretion. McA-RH7777 cells, when cul-
tured in the presence of exogenous oleate (18:1 n-9),
secreted TAG-rich VLDL many fold higher as comparedSundaram and Yao Nutrition & Metabolism 2010, 7:35
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to no oleate supplementation [60,70,76,77]. However,
when the cells were treated with poly-unsaturated fatty
acids such as eicosapentaenoic acid (20:5 n-3), assembly
and secretion of TAG-rich VLDL was significantly
decreased [72]. The impaired secretion of apoB in cells
treated with docosahexaenoic acid (22:6 n-3) was associ-
ated with increased oxidation, aggregation and
autophagic degradation of apoB [78]. In rat primary
hepatocytes, treatment with chylomicron remnants rich
in saturated fatty acids or n-6 polyunsaturated fatty acids
were more potent in promoting TAG-rich VLDL secre-
tion than those rich in monounsaturated fatty acids [79].
HepG2 cells treated with a mixture of conjugated linoleic
acids synthesized and secreted significantly less apoB-100
as compared to treatment with saturated or polyunsatu-
rated fatty acids [80]. These studies suggest strongly that
the characteristics of different fatty acids have distinct
impacts on hepatic VLDL secretion.
The differential effects of fatty acid feeding on VLDL
production has also been observed in vivo in animal stud-
ies. For example, transgenic mice lacking LDL receptor
(Ldlr-/-) and expressing only apoB-100 responded differ-
ently in VLDL production to diet supplemented with
echium oil (rich in 18:4 n-3), fish oil (rich in 20:5 n-3 and
22:6 n-3) or palm oil (enriched in 16:0) [81]. Feeding mice
with diet supplemented with or without essential fatty
acids also resulted in production of VLDL particles with
different size and different catabolic rates [82].
Mechanisms by which certain fatty acid species prefer-
entially promote VLDL secretion remain to be defined.
Different fatty acid species may affect transcription of
genes involved in TAG synthesis [81], which in turn may
affect VLDL assembly and secretion. Acutely, treatment
with different fatty acids may generate TAG molecules
that are differentially utilized for VLDL assembly and
secretion. For examples, studies with McA-RH7777 cells
have shown that TAG derived from oleic acid (18:1 n-9)
was partitioned into microsomes and was effectively
secreted as VLDL, whereas TAG derived from eicosapen-
taenoic acid (20:5 n-3) was stored in the cytosol and was
poorly secreted [72]. The discriminative usage of certain
TAG molecules for VLDL assembly and secretion may be
attributable to compartmentalization [72]. However as
discussed below, because fatty acyl chains are also sub-
strates for membrane phospholipid biogenesis, it is possi-
ble that a membrane milieu that supports assembly,
t r a f f i c k i n g ,  a n d  m a t u r a t i o n  o f  T A G - r i c h  V L D L  i s
imparted by certain fatty acid species.
Besides the chemical nature of fatty acid species, the
duration and concentration of fatty acid treatment also
influence VLDL assembly and secretion. This could be as
a result of either fatty acid-induced lipotoxicity or fatty
acid-mediated transcription activation of lipid metabo-
lism genes. Feeding Ldlr-/- mice with conjugated linoleic
acid (10trans,12cis-18:2) for a short period of time
resulted in hypertriglyceridemia with elevated plasma
VLDL and HDL. However, long term feeding with the
same fatty acid decreased plasma VLDL associated TAG,
probably attributable to upregulated expression of
hepatic VLDL receptor, lipoprotein lipase, and fatty acid
translocase that could assist in the clearance of lipopro-
teins from circulation [83]. Prolonged incubation of
McA-RH7777 cells with high concentrations of oleic acid
also resulted in decreased apoB-100 secretion and
increased apo-B100 degradation through proteasomal
and non-proteasomal pathways, as a result of ER stress
associated with massive accumulation of intracellular
TAG [84]. Thus, overloading of lipids to the extent that
exceeds the capacity of hepatocytes to effectively assem-
ble and secrete VLDL would lead to impaired TAG secre-
tion and cause hepatosteatosis. In addition to fatty acid-
associated lipotoxicity, it has been reported recently that
hepatic overexpression of apoB also induce hepatic ER
stress and insulin resistance [85]. The molecular mecha-
nisms by which excess fatty acid influx and overproduc-
tion of apoB-100 lead to ER stress and altered insulin
signal transduction merits further investigation.
Glycerolipid biogenesis and VLDL assembly and 
secretion
Identification and characterization of glycerolipid synthe-
sis gene products have accelerated our understanding on
the impact of hepatic lipid synthesis and/or their avail-
ability on VLDL assembly and secretion. The rate limiting
step in the de novo biosynthesis of TAG and phospholip-
ids is catalyzed by phosphatidate phosphatase-1 (PAP-1)
[86], which converts phosphatidate to diacylglycerol that
is subsequently utilized for the synthesis of TAG and
phospholipids such as phosphatidylcholine (PC) and
phosphatidylethanolamine (PE). In mammals, PAP-1 is
encoded by the lipin gene family consisting of lipin-1, -2
and -3 [87,88]. In humans, lipin-1 is highly expressed in
skeletal muscles and adipose tissues; lipin-2 and -3 are
expressed in brain, liver, jejunum, placenta, and adipose
tissues [88]. The Lpin1  gene encodes two alternatively
spliced isoforms lipin-1α and -1β [89], and the expression
of  Lpin1  is upregulated by glucocorticoids and sup-
pressed by insulin [90]. Transient expression of lipin-1α
or -1β in McA-RH7777 cells resulted in increased synthe-
sis and secretion glycerolipids under basal or lipid-rich
conditions [91]. Secretion of TAG as VLDL1  was
increased upon lipin-1α or -1β expression when cells
were cultured under lipid-rich conditions [91]. These
results were not in accord with studies of hepatocytes iso-
lated from the Lipn1-deficiency fld (fatty liver lipodystro-
phy) mice, in which the rate of TAG synthesis was not
changed in the hepatocytes isolated from adult mice,
however, the rate of TAG synthesis increased in the hepa-Sundaram and Yao Nutrition & Metabolism 2010, 7:35
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tocytes isolated from 14-day-old fld  mice. Adenovirus
mediated Lipin-1 overexpression in the hepatocytes iso-
lated from adult fld mice resulted in the suppression of
VLDL-TAG secretion [92]. Moreover, adenovirus-medi-
ated lipin-1 overexpression in the obese, insulin-resistant
UCP-DTA mice resulted in decreased the fasting plasma
TAG concentration [92]. The reason for the discrepancy
between these studies regarding the role of lipin-1 in
V L D L  s e c r e t i o n  r e m a i n s  t o  b e  e x p l a i n e d .  I t  h a s  b e e n
shown that compartmentalization of lipin-1, in addition
to its PAP1 activity, also plays a role in VLDL assembly
and secretion [91]. Expression of a mutant form of lipin-
1α, in which the nuclear localization signal sequence was
removed, resulted in cytosolic presentation of the protein
and diminished stimulation of VLDL1  secretion [91].
Nuclear localization of lipin-1 is probably important for
transactivation of gene expression, as lipin-1 is known to
act as a transcription activator [93]. The dual function of
lipin-1 and its variable subcellular compartmentalization
with respect to VLDL assembly and secretion requires
further investigation.
The final step in the de novo synthesis of TAG is cata-
lyzed by acyl-CoA:diacylglycerol acyltransferase (DGAT).
Two  DGAT  genes encode the respective DGAT1 and
DGAT2, which are structurally unrelated and show
hepatic expression [94,95]. The DGAT1 knockout mouse
has a normal fasting plasma TAG level despite reduced
hepatic TAG [96]. Adenovirus mediated expression of
DGAT1 in mice increased TAG in the liver but did not
increase VLDL production [97]. However, overexpression
of human DGAT1 in McA-RH7777 cells resulted in
increased synthesis, cellular accumulation, and secretion
of TAG as VLDL [98,99]. Concomitantly, intracellular
degradation of apoB was decreased in DGAT1 overex-
pressing cells [98]. Overexpression of DGAT2 in McA-
RH7777 cells also resulted in increased secretion of TAG
and apoB [98], whereas knockdown of DGAT2 in mice
with antisense oligonucleotide decreased TAG and apoB
secretion as VLDL [100]. These studies suggest that
although TAG synthesis is important for promoting
VLDL production, the increased hepatic TAG may be
compartmentalized and thus not necessarily be available
for VLDL assembly or secretion.
Hepatic VLDL assembly and secretion is also pro-
foundly influenced by alterations in the de novo biosyn-
thesis of phospholipids, such as PE and PC. Two
pathways are involved in hepatic PC synthesis; the CDP-
choline pathway contributes approximately 70% of total
hepatic PC synthesis, whereas the remainder 30% is syn-
thesized through the PE methylation pathway. The PE
methylation pathway is catalyzed by PE N-methyltrans-
ferase (PEMT), a product of the Pemt2 gene. The Pemt2-/
- mouse had normal liver PC content as a result of com-
pensatory upregulation of CTP:phosphocholine cytidy-
lyltransferase (CCT) activity; hence these mice did not
display abnormal plasma lipid levels compared to control
mice [101]. It appears that as long as CCT activity is
intact, hepatic PC synthesis is uncompromised when the
P E M T  a c t i v i t y  i s  a b s e n t .  L a c k  o f  P E M T  i n  t h e  Ldlr-/-
background, however, resulted in a reduction of athero-
sclerosis incidence when the mice were fed with a high fat
diet for 16 weeks [102]. These reduced atherosclerotic
lesion development was attributed to lowered phospho-
lipid content in apoB-containing lipoproteins (e.g. VLDL,
IDL, and LDL) and reduced secretion of VLDL [102].
The rate limiting step in the CDP-choline pathway for
PC synthesis is catalyzed by CCT. At least three CCT iso-
forms are known in mammals and they are encoded by
two genes, namely Pcyt1α for CCTα and Pcyt1b for differ-
entially spliced transcripts CCTβ2 and CCTβ3 [103]. It
has been shown that plasma levels of HDL and VLDL
were markedly reduced in mice lacking hepatic CCTα
expression [104], indicating that the activity of hepatic
CCT is an important determinant of VLDL and HDL in
vivo. However, reconstituted CCTα in the knock-out
hepatocytes by ex vivo infection with adenovirus encod-
ing CCTα failed to stimulate VLDL secretion even
t hough ce llular PC leve ls ret urned to normal [105]. In
contrary, adenoviral delivery of CCTα into knock-out
mice normalized plasma HDL and VLDL [105]. The
CCTα activity is thus required for lipoprotein metabo-
lism in vivo.
Hepatic PE synthesis is likewise achieved through the
CDP-ethanolamine pathway, in which CTP:phosphoeth-
anolamine cytidylyltransferase (encoded by Pcyt2) cata-
lyzes the rate regulatory step for the formation of CDP-
ethanolamine [106]. Reduced CDP-ethanolamine synthe-
sis in Pcyt2+/- mice resulted in elevated plasma VLDL (at
32-36 weeks old), as well as progressive development of
hepatosteatosis, obesity, and insulin resistance [107]. The
increased hepatic TAG synthesis and secretion in Pcyt2+/-
mice are probably attributable to increased availability of
diacylglycerol (as a result of limited CDP-ethanolamine)
[107].
Because phospholipid synthesis not only supplies lipid
substrates for VLDL but also contributes to the biogene-
sis and maintenance of ER/Golgi membranes, it impacts
both the cargo and trafficking machinery for VLDL
assembly and secretion. Studies with genetically modified
mice lacking both PEMT and multiple drug-resistant
protein 2 have suggested that the PE/PC ratio is a key reg-
ulator of cell membrane integrity in the liver and plays a
role in the progression of steatosis into steatohepatitis
[108]. It remains to be determined whether or not the
composition of phospholipid species in the ER/Golgi
membranes affects VLDL assembly/secretion.Sundaram and Yao Nutrition & Metabolism 2010, 7:35
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VLDL assembly and secretion influenced by 
vesicular trafficking factors
Protein factors involved in intracellular vesicular traffick-
ing, primarily the small GTPase proteins, play a profound
role in VLDL assembly and secretion. The requirement of
COPII coated vesicles for apoB exiting from the ER has
been demonstrated by an in vitro ER budding assay [109].
Formation of COPII coated vesicles is initiated by the
GTPase Sar1 protein. Deficiency of Sar1 has been linked
to intestinal apoB-lipoprotein secretion disorder known
as chylomicron retention disease in humans [110].
E x p r e s s i o n  o f  a  G D P - r e s t r i c t e d  m u t a n t  ( T 3 9 N )  o f  t h e
Sar1 protein in McA-RH7777 cells prevented ER exit of
apoB [109]. The anterograde transport from the Golgi
apparatus is driven by the small GTPase, ADP ribosyla-
tion factor 1 (ARF1). Expression of a dominant-negative
T31N mutant of ARF1 in McA-RH7777 cells resulted
80% reduction in the assembly of apoB-100 VLDL1 along
with the loss of COPI from the Golgi apparatus. Overex-
pression of ARF1 in the cells resulted in an oleate dose
dependent increase in VLDL1 secretion with a concomi-
tant decrease in VLDL2 secretion [111].
The activities of two phospholipases have been shown
to play a role in VLDL maturation, the calcium indepen-
dent phospholipase A2 (iPLA2β) and phospholipase D
(PLD1) [71,72,112]. The iPLA2β is an intracellular protein
that does not have a Ca2+-dependent lipid-binding
domain but contains ankyrin repeats that may mediate
membrane binding. Inhibition of iPLA2β with chemical
inhibitors or antisense RNA interfered with the forma-
tion of TAG-rich VLDL1 but not dense VLDL particles
such as VLDL2 [71,72]. The PLD1 catalyzes the hydrolysis
of PC to produce PA and choline and is activated by
ARF1. Inactivation of PLD1 activity (and thus the forma-
tion of PA) in cultured hepatic cells using chemical inhib-
itors also blocked VLDL formation [71,72]. Likewise,
expression of aberrant ARF1 that lost PLD1-activation
function [111] or treatment with brefeldin A (an inhibitor
of ARF1) [56,113] effectively prevented TAG-rich VLDL
secretion with little effect on the secretion of denser par-
ticles. These results suggest that maturation of VLDL
probably not only requires sufficient lipid substrate avail-
ability, but also depends upon the protein factors that
effectively mediate the fusion between lipid droplets and
apoB to form TAG-rich VLDL. The fusion events pre-
sumably require coordinated synthesis and fusion of vesi-
cle themselves, as well as synthesis and fusion of cargo
(i.e. lipid droplets and VLDL precursors) within the vesi-
cles. Factors within the microsomal lumen that are
responsible for cargo fusion during the final step of
VLDL1 maturation remain to be determined.
Cytosolic lipid droplet-associated proteins 
affecting VLDL assembly and secretion
Multiple protein factors that are found in association
with cytosolic lipid droplets also influence VLDL assem-
bly and secretion. Adipocyte differentiation-related pro-
tein (ADRP) is the major protein associated with
cytosolic lipid droplets. Overexpression of ADRP in
McA-RH7777 cells resulted in increased accumulation of
cytosolic lipid droplets and a corresponding decrease in
VLDL secretion [114]. Although the molecular mecha-
nism responsible for the inhibitory effect of ADRP
expression on VLDL secretion remains to be defined, it is
possible that enlargement of cytosolic lipid droplets may
diminish the microsomal TAG pool for VLDL secretion.
Recently, another lipid droplet associated protein
CideB has been suggested to play a role in VLDL assem-
bly and secretion [115]. CideB is a member of Cide (cell
death-inducing DFFA45 (DNA fragmentation factor 45)-
like effector) family that also includes CideA, and CideC
(or Fsp27). While CideA is expressed at high levels in
brown adipose tissue, CideB mRNA and proteins are
detected in various tissues with the highest level of
expression in the liver. Hepatic CideB exists as a smooth
ER- and lipid droplet-associated protein. Mice deficient
in CideA or CideB are resistant to high-fat diet-induced
obesity and diabetes [116]. The role of CideB in regulat-
ing lipid homeostasis has been studied with the Cideb-/-
mice. Compared with wildtype littermates, the Cideb-/-
mice exhibited an increase in hepatic TAG content and
reduced VLDL secretion [115]. Yeast two hybrid and co-
immunoprecipitation experiments have shown a physical
interaction between CideB and apoB [115]. These data
suggest that the cytosolic lipids droplets are functionally
in close contact with the ER where initial VLDL assembly
takes place.
Non-apoB apolipoproteins affecting VLDL 
assembly and secretion
In addition to apoB-100, hepatic VLDL particles also con-
tain other apolipoproteins such as apoE and apoC. ApoE
(299 amino acids) is a major protein constituent of TAG-
rich lipoproteins including VLDL and chylomicrons.
Experimental evidences obtained by several laboratories
working with apoE overexpressing transgenic mice [117-
119] or McA-RH7777 cells [120] have suggested that
apoE plays a role in the formation of fully lipidated VLDL.
The underlying mechanisms by which apoE expression
promotes VLDL assembly and secretion were unclear.
Recently, a detailed analysis conducted using McA-
RH7777 cells treated with apoE specific siRNA or pri-
mary hepatocytes isolated from apoE-/- mice have shown
that the assembly (within the Golgi apparatus) or secre-
tion of VLDL was independent of apoE expression [121].Sundaram and Yao Nutrition & Metabolism 2010, 7:35
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Thus, the VLDL-associated apoE in the Golgi apparatus
and media may not drive the formation of fully lipidated
VLDL.
Apolipoprotein C-III is a small (79 amino acids)
exchangeable apolipoprotein composed of multiple
amphipathic α-helices, and is expressed mainly in the
liver [122]. It has been reported recently that overexpres-
sion of human apoC-III in McA-RH7777 cells resulted in
the overproduction and secretion of VLDL-TAG and
VLDL-apoB under lipid rich conditions [76]. Overexpres-
sion of apoC-III also resulted in increased activity and
expression of MTP. The ability of apoC-III to stimulate
hepatic VLDL assembly and secretion was abolished by a
naturally occurring mutation Ala23Thr [123] that was
identified in human subjects with hypotriglyceridemia
[124]. Thus apoC-III, a component of VLDL and HDL,
appears to play an intracellular role in stimulating VLDL
assembly and secretion [76,123]. Mechanisms by which
apoC-III exerts the stimulatory effect on VLDL assembly
and secretion are unclear.
The human APOA5 gene is a part of the apolipoprotein
gene cluster that contains APOA1, APOC3, and APOA4
on chromosome 11 (11q23) [125]. Initial studies has
revealed association of single nucleotide polymorphisms
within the APOA5 locus with plasma TAG and VLDL in
humans, and the effect is not related to the neighboring
APOC3 gene markers [125]. Mice expressing the APOA5
transgene displayed a 65% decrease in plasma TAG levels;
whereas apoa5 knock-out mice showed a 4-fold increase
in plasma TAG concentration [125]. Thus, apoA-V (343
amino acids) has been viewed as a candidate gene regu-
lating plasma TAG concentrations [126]. Overexpression
of murine apoA-V in C57Bl/6 mice through adenovirus-
mediated gene transfer decreased VLDL production rate
in a dose-dependent manner by impairing apoB lipida-
tion [127]. In the same mouse model, overexpression of
a p o A - V  a l s o  r e s u l t e d  i n  d e c r e a s e d  p l a s m a  T A G  b y
enhancing lipoprotein lipase-mediated clearance of TAG-
rich lipoproteins [127]. Transfection studies showed that
recombinant apoA-V expressed in McA-RH7777 cells
was unexpectedly associated with cytosolic lipid droplets,
despite the fact that apoA-V possesses the signal peptide
and is a secretory protein [128]. The mechanisms
whereby apoA-V expression attenuates VLDL production
remain to be defined.
Lipoprotein receptors affecting VLDL assembly and 
secretion
Intracellular degradation of newly synthesized apoB-100
diminishes overall assembly and secretion of VLDL. The
LDL receptor, a ubiquitously expressed protein responsi-
ble for the clearance of cholesterol-rich lipoproteins from
blood stream through its ligands apoB-100 and apoE,
promotes intracellular degradation of apoB-100 resulting
in decreased VLDL secretion [129]. The loss of LDL
receptor activity in the liver cells leads to increased secre-
tion of VLDL particles, and the particles secreted are
small with reduced TAG content [130,131]. Thus, the
LDL receptor mediated apoB-100 degradation appears to
preferentially target underlipidated particles. Mecha-
nisms responsible for the LDL receptor mediated apoB-
100 degradation may involve (i) rapid reuptake of nascent
VLDL particles on the cell surface [129,132] and (ii) intra-
cellular targeting of nascent VLDL particles to degrada-
tion [129,133]. Both mechanisms appear to require exit of
apoB-100 from the ER and interaction of apoE or apoB-
100 with the LDL receptor [134].
Expression and function of LDL receptor are negatively
regulated by proprotein convertase subtilisin kexin type 9
(PCSK9) [135,136]. Attempts were made to determine
whether the level of PCSK9 expression would affect apoB
secretion or intracellular degradation. Transfection stud-
ies with McA-RH7777 cells that stably expressed the
D374Y mutant form of PCSK9 (identified in human
familial hypercholesterolemia) showed that the patho-
genic variant expression resulted in increased secretion
of apoB-100 lipoproteins (by 2-4-fold) but expression of
the wildtype PCSK9 did not increase apoB-100 secretion
[137]. These results might be interpreted as reduced deg-
radation of nascent apoB-100 protein mediated by the
L D L  r e c e p t o r .  L a c k  o f  a n  e f f e c t  o f  w i l d t y p e  P C S K 9
expression on apoB-100 secretion was also observed in
transfection studies with the human hepatoma HuH7
cells [138]. Likewise, secretion of apoB-100 from primary
hepatocytes of wildtype or Pcsk9-/- mice was not signifi-
cantly different [139]. The possible link between PCSK9,
LDL receptor, and hepatic apoB-100 secretion remains to
be determined.
Genetic absence of functional ATP binding cassette
transporter A1 (ABCA1) in Tangier disease is associated
with severely lowered plasma HDL and concomitantly
elevated plasma TAG concentrations [140]. This meta-
bolic abnormality has been recapitulated recently in
McA-RH7777 cells where the ABCA1 was silenced using
siRNA [141]. Unexpectedly, supplementation of culture
media of the ABCA1 knockdown cells with nascent large
HDL decreased the secretion of buoyant VLDL1 particles
[141]. It appears that the large HDL, assembled by
hepatic ABCA1, can attenuate VLDL secretion through
the phosphoinositide 3 kinase (PI3K)-dependent signal-
ing pathway [141]. This study is reminiscent of a previous
observation that the PI3K activity is required for insulin-
dependent inhibition of apoB secretion from primary rat
hepatocytes [142].
Scavenger receptor B1 (SR-B1) is a receptor for selec-
tive uptake of HDL cholesterol and is also known to
mediate the catabolism of apoB-containing lipoproteins.
Overexpression of SR-B1 in mice via adenovirus-medi-Sundaram and Yao Nutrition & Metabolism 2010, 7:35
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ated infection resulted in increased plasma concentra-
tions of VLDL-TAG and VLDL-apoB [143]. On the other
hand, disruption of the Scarb1 gene expression in mice
resulted in reduced VLDL production as well as MTP
activity [143], suggesting that hepatic SR-B1 expression is
closely linked to VLDL production.
Overall, the involvement of various lipoprotein recep-
tors in regulating VLDL assembly and secretion has grad-
ually been revealed, which introduces another level of
complexity to the regulation of hepatic TAG homeostasis.
Because these lipoprotein receptors are intimately
involved in the metabolism of cholesterol (and phospho-
lipids as well), such as uptake, efflux, and intracellular
trafficking, it is possible that hepatic VLDL assembly and
secretion are influenced by cellular cholesterol metabo-
lism and related signaling events. The interrelationship
between TAG and cholesterol metabolism and its link to
VLDL assembly and secretion merits further investiga-
tion.
Altered insulin and leptin signaling affecting VLDL 
assembly and secretion
Hepatic VLDL overproduction and impairment in catab-
olism/clearance of TAG-rich lipoproteins from circula-
tion represent the two major contributors to
hypertriglyceridemia. Many patients with hypertriglycer-
idemia manifest elevated plasma T AG, accumulation of
small dense LDL particles and reduced HDL cholesterol
particles, all of which are closely associated with cardio-
vascular diseases [144]. The other traits associated with
hypertriglyceridemia include visceral obesity and insulin
resistance, which further exacerbate the aberrant over-
p r od u ct i o n  o f  V LD L  as  a  r e s u l t  o f  e x c e s s  fl ux  o f  f a t t y
acids (derived partly from lipolysis of plasma T AG-rich
lipoproteins) into the liver. Overall, insulin treatment
decreases hepatic VLDL production by limiting fatty acid
influx into the liver, decreasing the stability of apoB, and
promoting the posttranslational degradation of apoB, a
process mediated through the PI3-K pathway [145].
Overproduction of hepatic VLDL that results from the
loss of insulin responsiveness is often seen in insulin
resistance conditions, which is associated with increased
posttranslational stability of apoB-100 [145]. The insensi-
tivity of liver cells to insulin mediated suppression of
VLDL assembly is observed in fructose-induced insulin
resistant hamster model [146], where insulin resistance is
accompanied with hepatic inflammation. The fructose-
induced, insulin-resistant hamsters exhibited reduced
levels of the inhibitor of nuclear factor-κB (IκB) which
resulted in a concomitant activation of the inflammatory
nuclear factor-κB (NF-κB) cascade. Inhibition of NF-κB
cascade with chemical inhibitors also resulted in
decreased synthesis of apoB-100 in primary hepatocytes
and HepG2 cells, and was probably attributable to the
activation of insulin signaling and enhanced proteasomal
degradation of apoB-100 [147]. On the other hand, acti-
vation of the NF-κB pathway, via adenovirus-mediated
IκB kinase overexpression, resulted in increased apoB-
100 synthesis as a result of suppressed insulin signaling
through the NF-κB pathway [147]. Thus, there is an
important link between the inflammatory IκB kinase-NF-
κB signaling cascade, insulin signaling, and hepatic
apoB100 synthesis and secretion.
The insensitivity of liver cells to insulin-mediated sup-
pr es s ion of  VLDL as se mbl y is  a lso obse rved i n l ept in-
deficient obese mouse (ob/ob) [148]. Leptin is an adipose
derived hormone that plays a key role in energy intake
and expenditure. The leptin-deficient ob/ob mice and the
leptin receptor-deficient db/db  mice have been used
extensively as model systems to study their roles in VLDL
assembly and secretion [149]. The in vivo secretion rates
of TAG and apoB were reduced in both male and female
ob/ob mice as compared to their littermates. However, in
db/db obese mice, only male mice showed reduced secre-
tion of TAG. In ob/ob  mice and db/db  obese females,
there was a small increase in apoB-100 secretion and no
difference in apoB48 secretion. In these animals, the
main cause of dyslipidemia was due to the impaired
removal of VLDL from the circulation [149].
The ob/ob and db/db mice have been used to determine
diet or protein factors that influence the pathophysiology
of lipoprotein metabolism. For instance, the db/db mice
have been crossed with mice expressing human choles-
teryl ester transfer protein (CETP); the resulting mice dis-
played lowered levels of VLDL and LDL and became
resistant to diet-induced atherosclerosis as compared to
controls [150]. These results ascribe an anti-atherogenic
role for CETP under diabetic obese conditions. The ob/ob
mice crossed into the LDL receptor knockout back-
ground (Ldlr-/-) showed severe hyperlipidemia and spon-
taneous atherosclerosis, which was associated with
increased hepatic TAG production, delayed VLDL clear-
ance, and decreased hepatic uptake of LDL [151]. The db/
db mice have also been used as a model to study diet-
induced nonalcoholic steatohepatitis (NASH). Feeding
db/db  mice with methionine- and choline-deficient
(MCD) diet induced liver injury [152,153], and were
probably attributable to impaired hepatic secretion of
VLDL [154]. The MCD-fed db/db  mice developed
hepatic steatosis and displayed insulin resistance that is
severer than MCD-fed control mice [153]. These studies
indicate that increased fatty acid uptake together with
decreased secretion of VLDL represent the major insult
that lead to hepatic TAG accumulation under MCD diet
conditions.
Liver × receptor α (LXRα), the master regulator of lipid
metabolism [155], also regulates hepatic VLDL produc-
tion. Activation of LXR in hamsters fed with an LXR ago-Sundaram and Yao Nutrition & Metabolism 2010, 7:35
http://www.nutritionandmetabolism.com/content/7/1/35
Page 11 of 17
nist resulted in markedly increased plasma TAG and
VLDL and enhanced expression of sterol response ele-
ment binding protein-1c (SREBP-1c) and its target lipo-
genesis genes including steroyl CoA desaturase and fatty
acid synthase [156]. Furthermore, LXR activation also led
to enhanced stability of newly synthesized apoB and
increased secretion of TAG-rich VLDL-apoB. Increased
stability of apoB-100 was probably achieved through
attenuated insulin receptor and insulin receptor sub-
strate-1 tyrosine phosphorylation and concomitant
increases in protein tyrosine phosphatase 1B [156].
Studies with rats have shown that acute leptin treat-
ment, like that of insulin, lowered plasma VLDL-associ-
ated TAG [157,158]. However, the molecular mechanism
responsible for the leptin-induced hypotriglyceridemia
may be distinct from that of insulin. The leptin treatment
resulted in decreased lipogenesis and enhanced β-oxida-
tion, thus limiting lipid substrate for VLDL assembly/
secretion without affecting hepatic apoB levels [159,160].
On the other hand, insulin treatment had no effect on β-
oxidation but decreased hepatic apoB levels [160], proba-
bly owning to enhanced posttranslational degradation of
apoB. In summary, hepatic VLDL production is pro-
moted under conditions where post-translational stability
of apoB is augmented (e.g. enhanced lipid substrate sup-
ply), and its production is suppressed when post-transla-
tional degradation of apoB is increased (e.g. decreased
lipid substrate availability).
Intracellular degradation of newly synthesized 
apoB
Intracellular degradation of apoB refers to a process
whereby the newly synthesized apoB proteins are
degraded prior to secretion. It has been shown that apoB
degradation occurs during and after the protein transla-
tion, and the co- and post-translational degradation of
apoB takes place in both ER and post-ER compartments.
Attenuated intracellular degradation of newly synthe-
sized apoB is accompanied with increased VLDL produc-
tion, as often observed under chronic hyperinsulinemia
and insulin resistance conditions [161,162]. Under condi-
tions unfavorable for apoB folding or lipid assembly, the
newly synthesized apoB polypeptide undergoes ubiq-
uitin-mediated proteasomal degradation [56,163-165].
Lack of sufficient lipid supply or availability often triggers
the degradation process. Under certain conditions, apoB
degradation occurs even after an assembly intermediate
(i.e. a VLDL precursor) has already been assembled (for
extensive review on apoB degradation see [166-169]).
Non-proteasomal degradation pathway for apoB has
been described which involves autophagosomes
[170,171]. Autophagosomes are membrane structures
that encase and target intracellular substrates to lyso-
somes for disposal, a process termed autophagy [172].
The involvement of autophagy process for apoB degrada-
tion appears to be pronounced when ubiquitin/protea-
some pathway is inhibited, and the apoB proteins
accumulated in the crescent-shaped structures that are in
close proximity to cytosolic lipid droplets [173]. It has
been postulated that the crescent structures are the sites
where proteasomal and autophagosomal pathways con-
verge [173]. The autophagy mediated apoB degradation
has also been suggested in cells treated with n-3 fatty
acids such as docosahexaenoic acid (22:6 n-3), and under
this condition apoB also undergoes aggregation and oxi-
dation [78]. As mentioned earlier, the n-3 fatty acid
induced intracellular apoB degradation is probably
related to the poor utilization of TAG molecules for
VLDL assembly and secretion [72]. Missense mutations
within the βα1 domain of apoB also resulted in increased
degradation through autophagy [50], which presumably
resulted from impaired secretion of the mutant apoB as
lipoproteins.
In summary, in addition to the ubiquitin/proteasome
pathway presumably responsible for ER-associated degra-
dation of misfolded apoB polypeptides, the autophago-
some-mediated apoB and apoB-lipoprotein degradation
may represent an alternative pathway (post-ER degrada-
tion) for the disposal of aborted assembly intermediates.
Since augmented intracellular degradation of apoB and
apoB-lipoproteins is a potential means to suppress over-
production of the atherogenic VLDL/LDL, further stud-
ies are merited to identify and characterize factors
involved in autophagy-mediated apoB degradation.
Concluding remarks and perspectives
The past three decades have witnessed a tremendous
advancement in our knowledge and understanding of
protein and lipids factors that influence VLDL assembly
and secretion. Amino acid sequences within apoB-100,
particularly the N-terminal βα1 domain and the β-sheet
enriched β1 domain, have been recognized as functional
elements governing VLDL assembly/secretion. The role
of MTP in facilitating lipid mobilization into the
microsomal lumen and that of protein factors (e.g. apoC-
III) in promoting bulk TAG incorporation during VLDL
maturation is being revealed. In addition, enzymes that
are directly involved in hepatic lipogenesis and glycero-
lipids biogenesis, such as lipin-1 and DGAT among oth-
ers, have been cloned and characterized. Delineation and
c h a r a c t e r i z a t i o n  o f  r e g u l a t o r y  p a t h w a y s  o f  t h e s e  l i p i d
synthesis enzymes have provided molecular explanations
for hormonal regulation (e.g. insulin and glucocorticoids)
of VLDL assembly and secretion. Moreover, a compre-
hensive view of the interplay among various transcription
factors (e.g. SREBP-1, LXR, PPAR, and PGC-1) in regu-
lating hepatic lipogenesis, β-oxidation, and glycerolipids
biogenesis has begun to emerge, and their implications toSundaram and Yao Nutrition & Metabolism 2010, 7:35
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VLDL assembly/secretion under stress conditions require
further investigation. Finally ,  n ew  m ec h a n i s m s  s u c h  as
proteasomes and autophagosome that may play a role in
intracellular degradation of apoB thus attenuate hepatic
VLDL production have been suggested and also merit
additional studies. Various protein and lipid factors that
participate and influence hepatic VLDL assembly/secre-
tion are depicted in Fig. 2.
Other than understanding the biosynthesis of lipid sub-
strates required for VLDL assembly and secretion, a great
deal of knowledge has also accumulated with respect to
the temporal and spatial events associated with lipid
incorporation into VLDL. It is clear that VLDL precur-
sors are assembled within the ER and the maturation of
TAG-rich VLDL1 take place in post-ER compartments.
However, several questions remain unanswered. For
example, it is unclear about the biochemical origin(s) of
TAG or the relative contribution between the de novo
synthesis and the hydrolysis/re-esterification pathways
during VLDL maturation under normal or stress condi-
tions. It is also unclear what protein factors or membrane
structures are required for the mobilization of lumenal
TAG substrates or their delivery to VLDL precursors.
Although increasing evidence suggests that protein fac-
tors associated with cytosolic lipid droplets (e.g. CideB
and ADRP) may participate or influence lumenal VLDL
assembly, the cellular mechanisms through which the
cytosolic and lumenal components communicate remains
an enigma. Finally, knowledge gained from cell culture
and animal studies remains to be verified in humans with
advanced in vivo technologies to validate the pathophysi-
ological relevance.
Figure 2 Protein and lipid factors affecting VLDL assembly and secretion. The apoB polypeptide initiates lipid recruitment during translation and 
translocation (1); this process may or may not require the activity of MTP. The nascent apoB-lipid particle acquires, in a step-wise fashion, additional 
TAG (2). The activity of MTP is required for partitioning of TAG into the lumen (3) or the membranes of ER microsomes for VLDL assembly (4). The lu-
menal TAG substrate, referred to as "lumenal lipid droplet", exists in association with non-apoB apolipoproteins such as apoC-III (5). In addition to that 
synthesized from the de novo pathway (catalyzed by GPAT, AGPAT, PAP-1, and DGAT), the TAG substrate utilized for VLDL assembly is also derived 
from esterification of fatty acyl chains originated from TGH-mediated hydrolysis of existing storage and lumenal TAG pools (6) or from phospholipid 
turnover catalyzed by iPLA2 (7). The resulting VLDL precursor exits the ER through coatomer-mediated budding/vesiculation events (8), and matura-
tion of VLDL1 is achieved through ER/Golgi trafficking (9). Proteins associated with cytosolic lipid droplets, such as CideB and ADRP (10), influence VLDL 
assembly through an unknown mechanism. Molecular species of fatty acids have a profound impact on VLDL production; oleic acid (18:1 n-9) pro-
motes (11) whereas EPA (20:5 n-3) and DHA (22:6 n-3) attenuate (12) VLDL assembly/secretion. Misfolded apoB protein and aborted lipoprotein as-
sembly intermediates are targeted for intracellular degradation (13). Two degradative pathways, namely the ubiquitin/proteasome pathway (14) and 
autophagy (15), may involve formation of "crescent" structures that contain apoB and are in close association with cytosolic lipid droplets. ADRP, adi-
pocyte differentiation-related protein; AGPAT, acylglycerol-3-phosphate acyltransferase; CDP-C, CDP-choline; CDP-E, CDP-ethanolamine; CT, CTP:phos-
phocholine cytidylyltransferase; DAG, diacylglycerol; DGAT, acyl-CoA:diacylglycerol acyltransferase; ET, CTP:phosphoethanolamine cytidylyltransferase; 
G-3-P, glycerol-3-phosphate; GPAT, glycerol-3-phosphate acyltransferase; LPA, lysophosphatidate; LPC, lysophophatidylcholine; LPE, lysophosphati-
dylethanolamine; MTP, microsomal triglyceride-transfer protein; PAP-1, phosphatidate phosphatase-1; PC, phosphatidylcholine; P-cho, phosphocho-
line; PE, phosphatidylethanolamine; P-eth, phosphoethanolamine; TAG, triacylglycerol; VLDL, very low density lipoproteins.Sundaram and Yao Nutrition & Metabolism 2010, 7:35
http://www.nutritionandmetabolism.com/content/7/1/35
Page 13 of 17
List of abbreviations used
ABCA1: ATP binding cassette transporter A1; ADRP:
adipocyte differentiation-related protein; AGPAT: 1-acyl-
glycerol-3-phosphate O-acyltransferase; ARF1: ADP
ribosylation factor 1; CCT: CTP:phosphocholine cytidy-
lyltransferase; CETP: cholesteryl ester transfer protein;
DGAT: acyl-CoA:diacylglycerol acyltransferase; DHA:
docosahexaenoic acid; EPA: eicosapentaenoic acid; ER:
endoplasmic reticulum; FHBL: familial hypobetalipopro-
teinemia; GPAT: glycerol-3-phosphate acyltransferase;
HDL: high density lipoproteins; IDL: intermediate den-
sity lipoproteins; IκB: inhibitor of nuclear factor-κB; LDL:
low density lipoproteins; L-FABP: liver fatty acid binding
protein; LPA: lysophosphatidate; LXRα: liver × receptor
α; MCD: methionine- and choline-deficient; MTP:
microsomal triglyceride-transfer protein; NF-κB: nuclear
factor-κB; PA: phosphatidate; PAP-1: phosphatidate
phosphatase-1; PC: phosphatidylcholine; PCSK9: propro-
tein convertase subtilisin kexin type 9; PDI: protein disul-
fide isomerase; PE: phosphatidylethanolamine; PEMT: PE
N-methyltransferase; PGC: peroxisome proliferator-acti-
vated receptor gamma coactivator; PI3K: phosphoinosit-
ide 3 kinase; PPAR: peroxisome proliferator-activated
receptor; SHP: small heterodimer partner; SR-B1: scaven-
ger receptor B1; SREBP: sterol regulatory element bind-
ing protein; TAG: triacylglycerol; TGH: triacylglycerol
hydrolase; VLDL: very low density lipoproteins.
Authors' information
Meenakshi Sundaram, PhD, Research Associate, Depart-
ment of Biochemistry, Microbiology and Immunology,
University of Ottawa
Zemin Yao, PhD, Professor and Chair, Department of
Biochemistry, Microbiology and Immunology, Ottawa
Institute of Systems Biology, University of Ottawa
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
Both MS and ZY drafted, edited, and final approved the manuscript.
Acknowledgements
This work is supported by Canadian Institutes of Health Research Grant NMD-
15486. Z.Y. was a recipient of the Career Investigator award from the Heart and 
Stroke Foundation of Ontario.
Author Details
1Department of Biochemistry, Microbiology and Immunology, Ottawa Institute 
of Systems Biology, University of Ottawa, 451 Smyth Road, Ottawa, Ontario K1H 
8M5, Canada and 2Department of Pathology and Laboratory Medicine, 
University of Ottawa, 451 Smyth Road, Ottawa, Ontario K1H 8M5, Canada
References
1. Law SW, Lackner KJ, Hospattankar AV, Anchors JM, Sakaguchi AY, Naylor 
SL, Brewer HB Jr: Human apolipoprotein B-100: cloning, analysis of liver 
mRNA, and assignment of the gene to chromosome 2.  Proc Natl Acad 
Sci USA 1985, 82:8340-8344.
2. Lusis AJ, West R, Mehrabian M, Reuben MA, LeBoeuf RC, Kaptein JS, 
Johnson DF, Schumaker VN, Yuhasz MP, Schotz MC, et al.: Cloning and 
expression of apolipoprotein B, the major protein of low and very low 
density lipoproteins.  Proc Natl Acad Sci USA 1985, 82:4597-4601.
3. Deeb SS, Disteche C, Motulsky AG, Lebo RV, Kan YW: Chromosomal 
localization of the human apolipoprotein B gene and detection of 
homologous RNA in monkey intestine.  Proc Natl Acad Sci USA 1986, 
83:419-422.
4. Chen SH, Habib G, Yang CY, Gu ZW, Lee BR, Weng SA, Silberman SR, Cai SJ, 
Deslypere JP, Rosseneu M, et al.: Apolipoprotein B-48 is the product of a 
messenger RNA with an organ-specific in-frame stop codon.  Science 
1987, 238:363-366.
5. Kane JP, Hardman DA, Paulus HE: Heterogeneity of apolipoprotein B: 
isolation of a new species from human chylomicrons.  Proc Natl Acad Sci 
USA 1980, 77:2465-2469.
6. Tennyson GE, Sabatos CA, Higuchi K, Meglin N, Brewer HB Jr: Expression 
of apolipoprotein B mRNAs encoding higher- and lower-molecular 
weight isoproteins in rat liver and intestine.  Proc Natl Acad Sci USA 1989, 
86:500-504.
7. Segrest JP, Jones MK, De LH, Dashti N: Structure of apolipoprotein B-100 
in low density lipoproteins.  J Lipid Res 2001, 42:1346-1367.
8. Mann CJ, Anderson TA, Read J, Chester SA, Harrison GB, Kochl S, Ritchie PJ, 
Bradbury P, Hussain FS, Amey J, et al.: The structure of vitellogenin 
provides a molecular model for the assembly and secretion of 
atherogenic lipoproteins.  J Mol Biol 1999, 285:391-408.
9. Jiang ZG, Gantz D, Bullitt E, McKnight CJ: Defining lipid-interacting 
domains in the N-terminal region of apolipoprotein B.  Biochemistry 
2006, 45:11799-11808.
10. Dashti N, Gandhi M, Liu X, Lin X, Segrest JP: The N-terminal 1000 residues 
of apolipoprotein B associate with microsomal triglyceride transfer 
protein to create a lipid transfer pocket required for lipoprotein 
assembly.  Biochemistry 2002, 41:6978-6987.
11. Jiang ZG, Simon MN, Wall JS, McKnight CJ: Structural analysis of 
reconstituted lipoproteins containing the N-terminal domain of 
apolipoprotein B.  Biophys J 2007, 92:4097-4108.
12. Ren G, Rudenko G, Ludtke SJ, Deisenhofer J, Chiu W, Pownall HJ: Model of 
human low-density lipoprotein and bound receptor based on cryoEM.  
Proc Natl Acad Sci USA 2010, 107:1059-1064.
13. Hussain MM, Bakillah A, Nayak N, Shelness GS: Amino acids 430-570 in 
apolipoprotein B are critical for its binding to microsomal triglyceride 
transfer protein.  J Biol Chem 1998, 273:25612-25615.
14. Segrest JP, Jones MK, Dashti N: N-terminal domain of apolipoprotein B 
has structural homology to lipovitellin and microsomal triglyceride 
transfer protein: a "lipid pocket" model for self-assembly of apob-
containing lipoprotein particles.  J Lipid Res 1999, 40:1401-1416.
15. Liang J, Ginsberg HN: Microsomal triglyceride transfer protein binding 
and lipid transfer activities are independent of each other, but both are 
required for secretion of apolipoprotein B lipoproteins from liver cells.  
J Biol Chem 2001, 276:28606-28612.
16. Bradbury P, Mann CJ, Kochl S, Anderson TA, Chester SA, Hancock JM, 
Ritchie PJ, Amey J, Harrison GB, Levitt DG, et al.: A common binding site 
on the microsomal triglyceride transfer protein for apolipoprotein B 
and protein disulfide isomerase.  J Biol Chem 1999, 274:3159-3164.
17. Hussain MM, Bakillah A, Jamil H: Apolipoprotein B binding to 
microsomal triglyceride transfer protein decreases with increases in 
length and lipidation: implications in lipoprotein biosynthesis.  
Biochemistry 1997, 36:13060-13067.
18. Kreuzer J, White AL, Knott TJ, Jien ML, Mehrabian M, Scott J, Young SG, 
Haberland ME: Amino terminus of apolipoprotein B suffices to produce 
recognition of malondialdehyde-modified low density lipoprotein by 
the scavenger receptor of human monocyte-macrophages.  J Lipid Res 
1997, 38:324-342.
19. Sivaram P, Choi SY, Curtiss LK, Goldberg IJ: An amino-terminal fragment 
of apolipoprotein B binds to lipoprotein lipase and may facilitate its 
binding to endothelial cells.  J Biol Chem 1994, 269:9409-9412.
20. Shelness GS, Hou L, Ledford AS, Parks JS, Weinberg RB: Identification of 
the lipoprotein initiating domain of apolipoprotein B.  J Biol Chem 2003, 
278:44702-44707.
21. Wang L, Martin DD, Genter E, Wang J, McLeod RS, Small DM: Surface 
study of apoB1694-1880, a sequence that can anchor apoB to 
Received: 15 December 2009 Accepted: 27 April 2010 
Published: 27 April 2010
This article is available from: http://www.nutritionandmetabolism.com/content/7/1/35 © 2010 Sundaram and Yao; licensee BioMed Central Ltd.  This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Nutrition & Metabolism 2010, 7:35Sundaram and Yao Nutrition & Metabolism 2010, 7:35
http://www.nutritionandmetabolism.com/content/7/1/35
Page 14 of 17
lipoproteins and make it nonexchangeable.  J Lipid Res 2009, 
50:1340-1352.
22. Hospattankar AV, Law SW, Lackner K, Brewer HB Jr: Identification of low 
density lipoprotein receptor binding domains of human 
apolipoprotein B-100: a proposed consensus LDL receptor binding 
sequence of apoB-100.  Biochem Biophys Res Commun 1986, 
139:1078-1085.
23. Yang CY, Chen SH, Gianturco SH, Bradley WA, Sparrow JT, Tanimura M, Li 
WH, Sparrow DA, DeLoof H, Rosseneu M, et al.: Sequence, structure, 
receptor-binding domains and internal repeats of human 
apolipoprotein B-100.  Nature 1986, 323:738-742.
24. Wang L, Walsh MT, Small DM: Apolipoprotein B is conformationally 
flexible but anchored at a triolein/water interface: a possible model for 
lipoprotein surfaces.  Proc Natl Acad Sci USA 2006, 103:6871-6876.
25. Gretch DG, Sturley SL, Wang L, Lipton BA, Dunning A, Grunwald KA, 
Wetterau JR, Yao Z, Talmud P, Attie AD: The amino terminus of 
apolipoprotein B is necessary but not sufficient for microsomal 
triglyceride transfer protein responsiveness.  J Biol Chem 1996, 
271:8682-8691.
26. McLeod RS, Wang Y, Wang S, Rusinol A, Links P, Yao Z: Apolipoprotein B 
sequence requirements for hepatic very low density lipoprotein 
assembly. Evidence that hydrophobic sequences within 
apolipoprotein B48 mediate lipid recruitment.  J Biol Chem 1996, 
271:18445-18455.
27. Liang J, Wu X, Jiang H, Zhou M, Yang H, Angkeow P, Huang LS, Sturley SL, 
Ginsberg H: Translocation efficiency, susceptibility to proteasomal 
degradation, and lipid responsiveness of apolipoprotein B are 
determined by the presence of beta sheet domains.  J Biol Chem 1998, 
273:35216-35221.
28. Tran K, Boren J, Macri J, Wang Y, McLeod R, Avramoglu RK, Adeli K, Yao Z: 
Functional analysis of disulfide linkages clustered within the amino 
terminus of human apolipoprotein B.  J Biol Chem 1998, 273:7244-7251.
29. Huang XF, Shelness GS: Identification of cysteine pairs within the 
amino-terminal 5% of apolipoprotein B essential for hepatic 
lipoprotein assembly and secretion.  J Biol Chem 1997, 272:31872-31876.
30. Ingram MF, Shelness GS: Apolipoprotein B-100 destined for lipoprotein 
assembly and intracellular degradation undergoes efficient 
translocation across the endoplasmic reticulum membrane.  J Lipid Res 
1996, 37:2202-2214.
31. Taniguchi T, Ishikawa Y, Tsunemitsu M, Fukuzaki H: The structures of the 
asparagine-linked sugar chains of human apolipoprotein B-100.  Arch 
Biochem Biophys 1989, 273:197-205.
32. Vukmirica J, Nishimaki-Mogami T, Tran K, Shan J, McLeod RS, Yuan J, Yao Z: 
The N-linked oligosaccharides at the amino terminus of human apoB 
are important for the assembly and secretion of VLDL.  J Lipid Res 2002, 
43:1496-1507.
33. Dunphy JT, Linder ME: Signalling functions of protein palmitoylation.  
Biochim Biophys Acta 1998, 1436:245-261.
34. Hoeg JM, Meng MS, Ronan R, Demosky SJ Jr, Fairwell T, Brewer HB Jr: 
Apolipoprotein B synthesized by Hep G2 cells undergoes fatty acid 
acylation.  J Lipid Res 1988, 29:1215-1220.
35. Zhao Y, McCabe JB, Vance J, Berthiaume LG: Palmitoylation of 
apolipoprotein B is required for proper intracellular sorting and 
transport of cholesteroyl esters and triglycerides.  Mol Biol Cell 2000, 
11:721-734.
36. Vukmirica J, Tran K, Liang X, Shan J, Yuan J, Miskie BA, Hegele RA, Resh MD, 
Yao Z: Assembly and secretion of very low density lipoproteins 
containing apolipoprotein B48 in transfected McA-RH7777 cells. Lack 
of evidence that palmitoylation of apolipoprotein B48 is required for 
lipoprotein secretion.  J Biol Chem 2003, 278:14153-14161.
37. Schonfeld G: Familial hypobetalipoproteinemia: a review.  J Lipid Res 
2003, 44:878-883.
38. Heiss G, Tamir I, Davis CE, Tyroler HA, Rifkand BM, Schonfeld G, Jacobs D, 
Frantz ID Jr: Lipoprotein-cholesterol distributions in selected North 
American populations: the lipid research clinics program prevalence 
study.  Circulation 1980, 61:302-315.
39. McCormick SP, Fellowes AP, Walmsley TA, George PM: Apolipoprotein B-
32: a new truncated mutant of human apolipoprotein B capable of 
forming particles in the low density lipoprotein range.  Biochim Biophys 
Acta 1992, 1138:290-296.
40. Wagner RD, Krul ES, Tang J, Parhofer KG, Garlock K, Talmud P, Schonfeld G: 
ApoB-54.8, a truncated apolipoprotein found primarily in VLDL, is 
associated with a nonsense mutation in the apoB gene and 
hypobetalipoproteinemia.  J Lipid Res 1991, 32:1001-1011.
41. Pullinger CR, Hillas E, Hardman DA, Chen GC, Naya-Vigne JM, Iwasa JA, 
Hamilton RL, Lalouel JM, Williams RR, Kane JP: Two apolipoprotein B 
gene defects in a kindred with hypobetalipoproteinemia, one of which 
results in a truncated variant, apoB-61, in VLDL and LDL.  J Lipid Res 
1992, 33:699-710.
42. Krul ES, Parhofer KG, Barrett PH, Wagner RD, Schonfeld G: ApoB-75, a 
truncation of apolipoprotein B associated with familial 
hypobetalipoproteinemia: genetic and kinetic studies.  J Lipid Res 1992, 
33:1037-1050.
43. Farese RV Jr, Garg A, Pierotti VR, Vega GL, Young SG: A truncated species 
of apolipoprotein B, B-83, associated with hypobetalipoproteinemia.  J 
Lipid Res 1992, 33:569-577.
44. Fouchier SW, Sankatsing RR, Peter J, Castillo S, Pocovi M, Alonso R, 
Kastelein JJ, Defesche JC: High frequency of APOB gene mutations 
causing familial hypobetalipoproteinaemia in patients of Dutch and 
Spanish descent.  J Med Genet 2005, 42:e23.
45. Chen Z, Fitzgerald RL, Schonfeld G: Hypobetalipoproteinemic mice with 
a targeted apolipoprotein (Apo) B-27.6-specifying mutation: in vivo 
evidence for an important role of amino acids 1254-1744 of ApoB in 
lipid transport and metabolism of the apoB-containing lipoprotein.  J 
Biol Chem 2002, 277:14135-14145.
46. McLeod RS, Zhao Y, Selby SL, Westerlund J, Yao Z: Carboxyl-terminal 
truncation impairs lipid recruitment by apolipoprotein B100 but does 
not affect secretion of the truncated apolipoprotein B-containing 
lipoproteins.  J Biol Chem 1994, 269:2852-2862.
47. Burnett JR, Shan J, Miskie BA, Whitfield AJ, Yuan J, Tran K, McKnight CJ, 
Hegele RA, Yao Z: A novel nontruncating APOB gene mutation, R463W, 
causes familial hypobetalipoproteinemia.  J Biol Chem 2003, 
278:13442-13452.
48. Burnett JR, Zhong S, Jiang ZG, Hooper AJ, Fisher EA, McLeod RS, Zhao Y, 
Barrett PH, Hegele RA, van Bockxmeer FM, et al.: Missense mutations in 
APOB within the betaalpha1 domain of human APOB-100 result in 
impaired secretion of ApoB and ApoB-containing lipoproteins in 
familial hypobetalipoproteinemia.  J Biol Chem 2007, 282:24270-24283.
49. Tarugi P, Averna M, Di LE, Cefalu AB, Noto D, Magnolo L, Cattin L, Bertolini 
S, Calandra S: Molecular diagnosis of hypobetalipoproteinemia: an 
ENID review.  Atherosclerosis 2007, 195:e19-e27.
50. Zhong S, Magnolo AL, Sundaram M, Zhou H, Yao EF, Di LE, Loria P, Wang S, 
Bamji-Mirza M, Wang L, et al.: Nonsynonymous mutations within APOB 
in human familial hypobetalipoproteinemia: evidence for feedback 
inhibition of lipogenesis and postendoplasmic reticulum degradation 
of apolipoprotein B.  J Biol Chem 2010, 285:6453-6464.
51. Jamil H, Dickson JK Jr, Chu CH, Lago MW, Rinehart JK, Biller SA, Gregg RE, 
Wetterau JR: Microsomal triglyceride transfer protein. Specificity of lipid 
binding and transport.  J Biol Chem 1995, 270:6549-6554.
52. Wetterau JR, Combs KA, Spinner SN, Joiner BJ: Protein disulfide 
isomerase is a component of the microsomal triglyceride transfer 
protein complex.  J Biol Chem 1990, 265:9800-9807.
53. Wang L, Fast DG, Attie AD: The enzymatic and non-enzymatic roles of 
protein-disulfide isomerase in apolipoprotein B secretion.  J Biol Chem 
1997, 272:27644-27651.
54. Wetterau JR, Aggerbeck LP, Bouma ME, Eisenberg C, Munck A, Hermier M, 
Schmitz J, Gay G, Rader DJ, Gregg RE: Absence of microsomal 
triglyceride transfer protein in individuals with abetalipoproteinemia.  
Science 1992, 258:999-1001.
55. Read J, Anderson TA, Ritchie PJ, Vanloo B, Amey J, Levitt D, Rosseneu M, 
Scott J, Shoulders CC: A mechanism of membrane neutral lipid 
acquisition by the microsomal triglyceride transfer protein.  J Biol Chem 
2000, 275:30372-30377.
56. Zhou M, Fisher EA, Ginsberg HN: Regulated Co-translational 
ubiquitination of apolipoprotein B100. A new paradigm for 
proteasomal degradation of a secretory protein.  J Biol Chem 1998, 
273:24649-24653.
57. Wang Y, Tran K, Yao Z: The activity of microsomal triglyceride transfer 
protein is essential for accumulation of triglyceride within microsomes 
in McA-RH7777 cells. A unified model for the assembly of very low 
density lipoproteins.  J Biol Chem 1999, 274:27793-27800.
58. Rustaeus S, Stillemark P, Lindberg K, Gordon D, Olofsson SO: The 
microsomal triglyceride transfer protein catalyzes the post-Sundaram and Yao Nutrition & Metabolism 2010, 7:35
http://www.nutritionandmetabolism.com/content/7/1/35
Page 15 of 17
translational assembly of apolipoprotein B-100 very low density 
lipoprotein in McA-RH7777 cells.  J Biol Chem 1998, 273:5196-5203.
59. Gordon DA, Jamil H: Progress towards understanding the role of 
microsomal triglyceride transfer protein in apolipoprotein-B 
lipoprotein assembly.  Biochim Biophys Acta 2000, 1486:72-83.
60. Wang Y, McLeod RS, Yao Z: Normal activity of microsomal triglyceride 
transfer protein is required for the oleate-induced secretion of very low 
density lipoproteins containing apolipoprotein B from McA-RH7777 
cells.  J Biol Chem 1997, 272:12272-12278.
61. Kulinski A, Rustaeus S, Vance JE: Microsomal triacylglycerol transfer 
protein is required for lumenal accretion of triacylglycerol not 
associated with ApoB, as well as for ApoB lipidation.  J Biol Chem 2002, 
277:31516-31525.
62. Hebbachi A, Gibbons GF: Inactivation of microsomal triglyceride 
transfer protein impairs the normal redistribution but not the turnover 
of newly synthesized glycerolipid in the cytosol, endoplasmic 
reticulum and Golgi of primary rat hepatocytes.  Biochim Biophys Acta 
1999, 1441:36-50.
63. Chang BH, Liao W, Li L, Nakamuta M, Mack D, Chan L: Liver-specific 
inactivation of the abetalipoproteinemia gene completely abrogates 
very low density lipoprotein/low density lipoprotein production in a 
viable conditional knockout mouse.  J Biol Chem 1999, 274:6051-6055.
64. Raabe M, Veniant MM, Sullivan MA, Zlot CH, Bjorkegren J, Nielsen LB, 
Wong JS, Hamilton RL, Young SG: Analysis of the role of microsomal 
triglyceride transfer protein in the liver of tissue-specific knockout 
mice.  J Clin Invest 1999, 103:1287-1298.
65. Spann NJ, Kang S, Li AC, Chen AZ, Newberry EP, Davidson NO, Hui ST, 
Davis RA: Coordinate transcriptional repression of liver fatty acid-
binding protein and microsomal triglyceride transfer protein blocks 
hepatic very low density lipoprotein secretion without 
hepatosteatosis.  J Biol Chem 2006, 281:33066-33077.
66. Huang J, Iqbal J, Saha PK, Liu J, Chan L, Hussain MM, Moore DD, Wang L: 
Molecular characterization of the role of orphan receptor small 
heterodimer partner in development of fatty liver.  Hepatology 2007, 
46:147-157.
67. Hribal ML, Nakae J, Kitamura T, Shutter JR, Accili D: Regulation of insulin-
like growth factor-dependent myoblast differentiation by Foxo 
forkhead transcription factors.  J Cell Biol 2003, 162:535-541.
68. Kamagate A, Qu S, Perdomo G, Su D, Kim DH, Slusher S, Meseck M, Dong 
HH: FoxO1 mediates insulin-dependent regulation of hepatic VLDL 
production in mice.  J Clin Invest 2008, 118:2347-2364.
69. Wolfrum C, Stoffel M: Coactivation of Foxa2 through Pgc-1beta 
promotes liver fatty acid oxidation and triglyceride/VLDL secretion.  
Cell Metab 2006, 3:99-110.
70. Dolinsky VW, Douglas DN, Lehner R, Vance DE: Regulation of the 
enzymes of hepatic microsomal triacylglycerol lipolysis and re-
esterification by the glucocorticoid dexamethasone.  Biochem J 2004, 
378:967-974.
71. Tran K, Wang Y, DeLong CJ, Cui Z, Yao Z: The assembly of very low 
density lipoproteins in rat hepatoma McA-RH7777 cells is inhibited by 
phospholipase A2 antagonists.  J Biol Chem 2000, 275:25023-25030.
72. Tran K, Sun F, Cui Z, Thorne-Tjomsland G, St GC, Lapierre LR, McLeod RS, 
Jamieson JC, Yao Z: Attenuated secretion of very low density 
lipoproteins from McA-RH7777 cells treated with eicosapentaenoic 
acid is associated with impaired utilization of triacylglycerol 
synthesized via phospholipid remodeling.  Biochim Biophys Acta 2006, 
1761:463-473.
73. Robichaud JC, van d V, Yao Z, Trigatti B, Vance DE: Hepatic uptake and 
metabolism of phosphatidylcholine associated with high density 
lipoproteins.  Biochim Biophys Acta 2009, 1790:538-551.
74. Sato K, Cho Y, Tachibana S, Chiba T, Schneider WJ, Akiba Y: Impairment of 
VLDL secretion by medium-chain fatty acids in chicken primary 
hepatocytes is affected by the chain length.  J Nutr 2005, 
135:1636-1641.
75. Tachibana S, Sato K, Cho Y, Chiba T, Schneider WJ, Akiba Y: Octanoate 
reduces very low-density lipoprotein secretion by decreasing the 
synthesis of apolipoprotein B in primary cultures of chicken 
hepatocytes.  Biochim Biophys Acta 2005, 1737:36-43.
76. Sundaram M, Zhong S, Bou Khalil M, Links PH, Zhao Y, Iqbal J, Hussain MM, 
Parks RJ, Wang Y, Yao Z: Expression of apolipoprotein C-III in McA-
RH7777 cells enhances VLDL assembly and secretion under lipid-rich 
conditions.  J Lipid Res 2010, 51:150-161.
77. Tran K, Thorne-Tjomsland G, DeLong CJ, Cui Z, Shan J, Burton L, Jamieson 
JC, Yao Z: Intracellular assembly of very low density lipoproteins 
containing apolipoprotein B100 in rat hepatoma McA-RH7777 cells.  J 
Biol Chem 2002, 277:31187-31200.
78. Pan M, Maitin V, Parathath S, Andreo U, Lin SX, St GC, Yao Z, Maxfield FR, 
Williams KJ, Fisher EA: Presecretory oxidation, aggregation, and 
autophagic destruction of apoprotein-B: a pathway for late-stage 
quality control.  Proc Natl Acad Sci USA 2008, 105:5862-5867.
79. Lopez-Soldado I, Avella M, Botham KM: Differential influence of different 
dietary fatty acids on very low-density lipoprotein secretion when 
delivered to hepatocytes in chylomicron remnants.  Metabolism 2009, 
58:186-195.
80. Pal S, Takechi R, Ho SS: Conjugated linoleic acid suppresses the 
secretion of atherogenic lipoproteins from human HepG2 liver cells.  
Clin Chem Lab Med 2005, 43:269-274.
81. Zhang P, Boudyguina E, Wilson MD, Gebre AK, Parks JS: Echium oil 
reduces plasma lipids and hepatic lipogenic gene expression in 
apoB100-only LDL receptor knockout mice.  J Nutr Biochem 2008, 
19:655-663.
82. Werner A, Havinga R, Bos T, Bloks VW, Kuipers F, Verkade HJ: Essential 
fatty acid deficiency in mice is associated with hepatic steatosis and 
secretion of large VLDL particles.  Am J Physiol Gastrointest Liver Physiol 
2005, 288:G1150-G1158.
83. Degrace P, Moindrot B, Mohamed I, Gresti J, Du ZY, Chardigny JM, 
Sebedio JL, Clouet P: Upregulation of liver VLDL receptor and FAT/CD36 
expression in LDLR-/- apoB100/100 mice fed trans-10,cis-12 
conjugated linoleic acid.  J Lipid Res 2006, 47:2647-2655.
84. Ota T, Gayet C, Ginsberg HN: Inhibition of apolipoprotein B100 secretion 
by lipid-induced hepatic endoplasmic reticulum stress in rodents.  J 
Clin Invest 2008, 118:316-332.
85. Su Q, Tsai J, Xu E, Qiu W, Bereczki E, Santha M, Adeli K: Apolipoprotein 
B100 acts as a molecular link between lipid-induced endoplasmic 
reticulum stress and hepatic insulin resistance.  Hepatology 2009, 
50:77-84.
86. Carman GM, Han GS: Roles of phosphatidate phosphatase enzymes in 
lipid metabolism.  Trends Biochem Sci 2006, 31:694-699.
87. Peterfy M, Phan J, Xu P, Reue K: Lipodystrophy in the fld mouse results 
from mutation of a new gene encoding a nuclear protein, lipin.  Nat 
Genet 2001, 27:121-124.
88. Donkor J, Sariahmetoglu M, Dewald J, Brindley DN, Reue K: Three 
mammalian lipins act as phosphatidate phosphatases with distinct 
tissue expression patterns.  J Biol Chem 2007, 282:3450-3457.
89. Peterfy M, Phan J, Reue K: Alternatively spliced lipin isoforms exhibit 
distinct expression pattern, subcellular localization, and role in 
adipogenesis.  J Biol Chem 2005, 280:32883-32889.
90. Manmontri B, Sariahmetoglu M, Donkor J, Bou Khalil M, Sundaram M, Yao 
Z, Reue K, Lehner R, Brindley DN: Glucocorticoids and cyclic AMP 
selectively increase hepatic lipin-1 expression, and insulin acts 
antagonistically.  J Lipid Res 2008, 49:1056-1067.
91. Bou Khlail M, Sundaram M, Zhang HY, Links PH, Raven JF, Manmontri B, 
Sariahmetoglu M, Tran K, Reue K, Brindley DN, et al.: The level and 
compartmentalization of phosphatidate phosphatase-1 (lipin-1) 
control the assembly and secretion of hepatic VLDL.  J Lipid Res 2009, 
50:47-58.
92. Chen Z, Gropler MC, Norris J, Lawrence JC Jr, Harris TE, Finck BN: 
Alterations in hepatic metabolism in fld mice reveal a role for lipin 1 in 
regulating VLDL-triacylglyceride secretion.  Arterioscler Thromb Vasc Biol 
2008, 28:1738-1744.
93. Finck BN, Gropler MC, Chen Z, Leone TC, Croce MA, Harris TE, Lawrence JC 
Jr, Kelly DP: Lipin 1 is an inducible amplifier of the hepatic PGC-1alpha/
PPARalpha regulatory pathway.  Cell Metab 2006, 4:199-210.
94. Cases S, Stone SJ, Zhou P, Yen E, Tow B, Lardizabal KD, Voelker T, Farese RV 
Jr: Cloning of DGAT2, a second mammalian diacylglycerol 
acyltransferase, and related family members.  J Biol Chem 2001, 
276:38870-38876.
95. Cases S, Smith SJ, Zheng YW, Myers HM, Lear SR, Sande E, Novak S, Collins 
C, Welch CB, Lusis AJ, et al.: Identification of a gene encoding an acyl 
CoA:diacylglycerol acyltransferase, a key enzyme in triacylglycerol 
synthesis.  Proc Natl Acad Sci USA 1998, 95:13018-13023.
96. Smith SJ, Cases S, Jensen DR, Chen HC, Sande E, Tow B, Sanan DA, Raber J, 
Eckel RH, Farese RV Jr: Obesity resistance and multiple mechanisms of 
triglyceride synthesis in mice lacking Dgat.  Nat Genet 2000, 25:87-90.Sundaram and Yao Nutrition & Metabolism 2010, 7:35
http://www.nutritionandmetabolism.com/content/7/1/35
Page 16 of 17
97. Millar JS, Stone SJ, Tietge UJ, Tow B, Billheimer JT, Wong JS, Hamilton RL, 
Farese RV Jr, Rader DJ: Short-term overexpression of DGAT1 or DGAT2 
increases hepatic triglyceride but not VLDL triglyceride or apoB 
production.  J Lipid Res 2006, 47:2297-2305.
98. Liang JJ, Oelkers P, Guo C, Chu PC, Dixon JL, Ginsberg HN, Sturley SL: 
Overexpression of human diacylglycerol acyltransferase 1, acyl-
coa:cholesterol acyltransferase 1, or acyl-CoA:cholesterol 
acyltransferase 2 stimulates secretion of apolipoprotein B-containing 
lipoproteins in McA-RH7777 cells.  J Biol Chem 2004, 279:44938-44944.
99. Yamazaki T, Sasaki E, Kakinuma C, Yano T, Miura S, Ezaki O: Increased very 
low density lipoprotein secretion and gonadal fat mass in mice 
overexpressing liver DGAT1.  J Biol Chem 2005, 280:21506-21514.
100. Liu Y, Millar JS, Cromley DA, Graham M, Crooke R, Billheimer JT, Rader DJ: 
Knockdown of acyl-CoA:diacylglycerol acyltransferase 2 with antisense 
oligonucleotide reduces VLDL TG and ApoB secretion in mice.  Biochim 
Biophys Acta 2008, 1781:97-104.
101. Walkey CJ, Donohue LR, Bronson R, Agellon LB, Vance DE: Disruption of 
the murine gene encoding phosphatidylethanolamine N-
methyltransferase.  Proc Natl Acad Sci USA 1997, 94:12880-12885.
102. Zhao Y, Su B, Jacobs RL, Kennedy B, Francis GA, Waddington E, Brosnan JT, 
Vance JE, Vance DE: Lack of phosphatidylethanolamine N-
methyltransferase alters plasma VLDL phospholipids and attenuates 
atherosclerosis in mice.  Arterioscler Thromb Vasc Biol 2009, 29:1349-1355.
103. Vance DE, Vance JE: Physiological consequences of disruption of 
mammalian phospholipid biosynthetic genes.  J Lipid Res 2009, 
50(Suppl):S132-S137.
104. Jacobs RL, Devlin C, Tabas I, Vance DE: Targeted deletion of hepatic 
CTP:phosphocholine cytidylyltransferase alpha in mice decreases 
plasma high density and very low density lipoproteins.  J Biol Chem 
2004, 279:47402-47410.
105. Jacobs RL, Lingrell S, Zhao Y, Francis GA, Vance DE: Hepatic 
CTP:phosphocholine cytidylyltransferase-alpha is a critical predictor of 
plasma high density lipoprotein and very low density lipoprotein.  J 
Biol Chem 2008, 283:2147-2155.
106. Poloumienko A, Cote A, Quee AT, Zhu L, Bakovic M: Genomic 
organization and differential splicing of the mouse and human Pcyt2 
genes.  Gene 2004, 325:145-155.
107. Fullerton MD, Hakimuddin F, Bonen A, Bakovic M: The development of a 
metabolic disease phenotype in CTP:phosphoethanolamine 
cytidylyltransferase-deficient mice.  J Biol Chem 2009, 284:25704-25713.
108. Li Z, Agellon LB, Allen TM, Umeda M, Jewell L, Mason A, Vance DE: The 
ratio of phosphatidylcholine to phosphatidylethanolamine influences 
membrane integrity and steatohepatitis.  Cell Metab 2006, 3:321-331.
109. Gusarova V, Brodsky JL, Fisher EA: Apolipoprotein B100 exit from the 
endoplasmic reticulum (ER) is COPII-dependent, and its lipidation to 
very low density lipoprotein occurs post-ER.  J Biol Chem 2003, 
278:48051-48058.
110. Jones B, Jones EL, Bonney SA, Patel HN, Mensenkamp AR, Eichenbaum-
Voline S, Rudling M, Myrdal U, Annesi G, Naik S, et al.: Mutations in a Sar1 
GTPase of COPII vesicles are associated with lipid absorption disorders.  
Nat Genet 2003, 34:29-31.
111. Asp L, Magnusson B, Rutberg M, Li L, Boren J, Olofsson SO: Role of ADP 
ribosylation factor 1 in the assembly and secretion of ApoB-100-
containing lipoproteins.  Arterioscler Thromb Vasc Biol 2005, 25:566-570.
112. Asp L, Claesson C, Boren J, Olofsson SO: ADP-ribosylation factor 1 and its 
activation of phospholipase D are important for the assembly of very 
low density lipoproteins.  J Biol Chem 2000, 275:26285-26292.
113. Rustaeus S, Lindberg K, Boren J, Olofsson SO: Brefeldin A reversibly 
inhibits the assembly of apoB containing lipoproteins in McA-RH7777 
cells.  J Biol Chem 1995, 270:28879-28886.
114. Magnusson B, Asp L, Bostrom P, Ruiz M, Stillemark-Billton P, Linden D, 
Boren J, Olofsson SO: Adipocyte differentiation-related protein 
promotes fatty acid storage in cytosolic triglycerides and inhibits 
secretion of very low-density lipoproteins.  Arterioscler Thromb Vasc Biol 
2006, 26:1566-1571.
115. Ye J, Li JZ, Liu Y, Li X, Yang T, Ma X, Li Q, Yao Z, Li P: Cideb, an ER- and lipid 
droplet-associated protein, mediates VLDL lipidation and maturation 
by interacting with apolipoprotein B.  Cell Metab 2009, 9:177-190.
116. Zhou Z, Yon TS, Chen Z, Guo K, Ng CP, Ponniah S, Lin SC, Hong W, Li P: 
Cidea-deficient mice have lean phenotype and are resistant to obesity.  
Nat Genet 2003, 35:49-56.
117. Kuipers F, Jong MC, Lin Y, Eck M, Havinga R, Bloks V, Verkade HJ, Hofker 
MH, Moshage H, Berkel TJ, et al.: Impaired secretion of very low density 
lipoprotein-triglycerides by apolipoprotein E- deficient mouse 
hepatocytes.  J Clin Invest 1997, 100:2915-2922.
118. Mensenkamp AR, Jong MC, van GH, Van Luyn MJ, Bloks V, Havinga R, 
Voshol PJ, Hofker MH, van Dijk KW, Havekes LM, et al.: Apolipoprotein E 
participates in the regulation of very low density lipoprotein-
triglyceride secretion by the liver.  J Biol Chem 1999, 274:35711-35718.
119. Maugeais C, Tietge UJ, Tsukamoto K, Glick JM, Rader DJ: Hepatic 
apolipoprotein E expression promotes very low density lipoprotein-
apolipoprotein B production in vivo in mice.  J Lipid Res 2000, 
41:1673-1679.
120. Huang Y, Liu XQ, Rall SC Jr, Taylor JM, von EA, Assmann G, Mahley RW: 
Overexpression and accumulation of apolipoprotein E as a cause of 
hypertriglyceridemia.  J Biol Chem 1998, 273:26388-26393.
121. Gusarova V, Seo J, Sullivan ML, Watkins SC, Brodsky JL, Fisher EA: Golgi-
associated maturation of very low density lipoproteins involves 
conformational changes in apolipoprotein B, but is not dependent on 
apolipoprotein E.  J Biol Chem 2007, 282:19453-19462.
122. Gangabadage CS, Zdunek J, Tessari M, Nilsson S, Olivecrona G, Wijmenga 
SS: Structure and dynamics of human apolipoprotein CIII.  J Biol Chem 
2008, 283:17416-17427.
123. Sundaram M, Zhong S, Bou Khalil M, Zhou H, Jiang ZG, Zhao Y, Iqbal J, 
Hussain MM, Figeys D, Wang Y, et al.: Functional analysis of the missense 
APOC3 mutation Ala23Thr associated with human 
hypotriglyceridemia.  J Lipid Res 2010 in press.
124. Liu H, Labeur C, Xu CF, Ferrell R, Lins L, Brasseur R, Rosseneu M, Weiss KM, 
Humphries SE, Talmud PJ: Characterization of the lipid-binding 
properties and lipoprotein lipase inhibition of a novel apolipoprotein 
C-III variant Ala23Thr.  J Lipid Res 2000, 41:1760-1771.
125. Pennacchio LA, Olivier M, Hubacek JA, Cohen JC, Cox DR, Fruchart JC, 
Krauss RM, Rubin EM: An apolipoprotein influencing triglycerides in 
humans and mice revealed by comparative sequencing.  Science 2001, 
294:169-173.
126. van Dijk KW, Rensen PC, Voshol PJ, Havekes LM: The role and mode of 
action of apolipoproteins CIII and AV: synergistic actors in triglyceride 
metabolism?  Curr Opin Lipidol 2004, 15:239-246.
127. Schaap FG, Rensen PC, Voshol PJ, Vrins C, van d V, Chamuleau RA, Havekes 
LM, Groen AK, van Dijk KW: ApoAV reduces plasma triglycerides by 
inhibiting very low density lipoprotein-triglyceride (VLDL-TG) 
production and stimulating lipoprotein lipase-mediated VLDL-TG 
hydrolysis.  J Biol Chem 2004, 279:27941-27947.
128. Shu X, Ryan RO, Forte TM: Intracellular lipid droplet targeting by 
apolipoprotein A-V requires the carboxyl-terminal segment.  J Lipid Res 
2008, 49:1670-1676.
129. Twisk J, Gillian-Daniel DL, Tebon A, Wang L, Barrett PH, Attie AD: The role 
of the LDL receptor in apolipoprotein B secretion.  J Clin Invest 2000, 
105:521-532.
130. James RW, Martin B, Pometta D, Fruchart JC, Duriez P, Puchois P, Farriaux 
JP, Tacquet A, Demant T, Clegg RJ, et al.: Apolipoprotein B metabolism in 
homozygous familial hypercholesterolemia.  J Lipid Res 1989, 
30:159-169.
131. Teusink B, Mensenkamp AR, van der BH, Kuipers F, van Dijk KW, Havekes 
LM: Stimulation of the in vivo production of very low density 
lipoproteins by apolipoprotein E is independent of the presence of the 
low density lipoprotein receptor.  J Biol Chem 2001, 276:40693-40697.
132. Williams KJ, Brocia RW, Fisher EA: The unstirred water layer as a site of 
control of apolipoprotein B secretion.  J Biol Chem 1990, 
265:16741-16744.
133. Jiang XC, Qin S, Qiao C, Kawano K, Lin M, Skold A, Xiao X, Tall AR: 
Apolipoprotein B secretion and atherosclerosis are decreased in mice 
with phospholipid-transfer protein deficiency.  Nat Med 2001, 
7:847-852.
134. Blasiole DA, Oler AT, Attie AD: Regulation of ApoB secretion by the low 
density lipoprotein receptor requires exit from the endoplasmic 
reticulum and interaction with ApoE or ApoB.  J Biol Chem 2008, 
283:11374-11381.
135. Seidah NG, Benjannet S, Wickham L, Marcinkiewicz J, Jasmin SB, Stifani S, 
Basak A, Prat A, Chretien M: The secretory proprotein convertase neural 
apoptosis-regulated convertase 1 (NARC-1): liver regeneration and 
neuronal differentiation.  Proc Natl Acad Sci USA 2003, 100:928-933.Sundaram and Yao Nutrition & Metabolism 2010, 7:35
http://www.nutritionandmetabolism.com/content/7/1/35
Page 17 of 17
136. Maxwell KN, Breslow JL: Adenoviral-mediated expression of Pcsk9 in 
mice results in a low-density lipoprotein receptor knockout 
phenotype.  Proc Natl Acad Sci USA 2004, 101:7100-7105.
137. Sun XM, Eden ER, Tosi I, Neuwirth CK, Wile D, Naoumova RP, Soutar AK: 
Evidence for effect of mutant PCSK9 on apolipoprotein B secretion as 
the cause of unusually severe dominant hypercholesterolaemia.  Hum 
Mol Genet 2005, 14:1161-1169.
138. Lalanne F, Lambert G, Amar MJ, Chetiveaux M, Zair Y, Jarnoux AL, 
Ouguerram K, Friburg J, Seidah NG, Brewer HB Jr, et al.: Wild-type PCSK9 
inhibits LDL clearance but does not affect apoB-containing lipoprotein 
production in mouse and cultured cells.  J Lipid Res 2005, 46:1312-1319.
139. Rashid S, Curtis DE, Garuti R, Anderson NN, Bashmakov Y, Ho YK, Hammer 
RE, Moon YA, Horton JD: Decreased plasma cholesterol and 
hypersensitivity to statins in mice lacking Pcsk9.  Proc Natl Acad Sci USA 
2005, 102:5374-5379.
140. Clee SM, Kastelein JJ, van DM, Marcil M, Roomp K, Zwarts KY, Collins JA, 
Roelants R, Tamasawa N, Stulc T, et al.: Age and residual cholesterol efflux 
affect HDL cholesterol levels and coronary artery disease in ABCA1 
heterozygotes.  J Clin Invest 2000, 106:1263-1270.
141. Chung S, Gebre AK, Seo J, Shelness GS, Parks JS: A novel role for ABCA1-
generated large pre-beta migrating nascent HDL in the regulation of 
hepatic VLDL triglyceride secretion.  J Lipid Res 2010, 51:729-742.
142. Phung TL, Roncone A, Jensen KL, Sparks CE, Sparks JD: Phosphoinositide 
3-kinase activity is necessary for insulin-dependent inhibition of 
apolipoprotein B secretion by rat hepatocytes and localizes to the 
endoplasmic reticulum.  J Biol Chem 1997, 272:30693-30702.
143. Wiersma H, Nijstad N, Gautier T, Iqbal J, Kuipers F, Hussain MM, Tietge UJ: 
Scavenger receptor BI facilitates hepatic very low density lipoprotein 
production in mice.  J Lipid Res 2010, 51:544-553.
144. Ginsberg HN: New perspectives on atherogenesis: role of abnormal 
triglyceride-rich lipoprotein metabolism.  Circulation 2002, 
106:2137-2142.
145. Meshkani R, Adeli K: Hepatic insulin resistance, metabolic syndrome 
and cardiovascular disease.  Clin Biochem 2009, 42:1331-1346.
146. Taghibiglou C, Carpentier A, Van Iderstine SC, Chen B, Rudy D, Aiton A, 
Lewis GF, Adeli K: Mechanisms of hepatic very low density lipoprotein 
overproduction in insulin resistance. Evidence for enhanced 
lipoprotein assembly, reduced intracellular ApoB degradation, and 
increased microsomal triglyceride transfer protein in a fructose-fed 
hamster model.  J Biol Chem 2000, 275:8416-8425.
147. Tsai J, Zhang R, Qiu W, Su Q, Naples M, Adeli K: Inflammatory NF-kappaB 
activation promotes hepatic apolipoprotein B100 secretion: evidence 
for a link between hepatic inflammation and lipoprotein production.  
Am J Physiol Gastrointest Liver Physiol 2009, 296:G1287-G1298.
148. Wiegman CH, Bandsma RH, Ouwens M, Sluijs FH van der, Havinga R, Boer 
T, Reijngoud DJ, Romijn JA, Kuipers F: Hepatic VLDL production in ob/ob 
mice is not stimulated by massive de novo lipogenesis but is less 
sensitive to the suppressive effects of insulin.  Diabetes 2003, 
52:1081-1089.
149. Li X, Grundy SM, Patel SB: Obesity in db and ob animals leads to 
impaired hepatic very low density lipoprotein secretion and 
differential secretion of apolipoprotein B-48 and B-100.  J Lipid Res 1997, 
38:1277-1288.
150. MacLean PS, Bower JF, Vadlamudi S, Osborne JN, Bradfield JF, Burden HW, 
Bensch WH, Kauffman RF, Barakat HA: Cholesteryl ester transfer protein 
expression prevents diet-induced atherosclerotic lesions in male db/
db mice.  Arterioscler Thromb Vasc Biol 2003, 23:1412-1415.
151. Coenen KR, Gruen ML, Hasty AH: Obesity causes very low density 
lipoprotein clearance defects in low-density lipoprotein receptor-
deficient mice.  J Nutr Biochem 2007, 18:727-735.
152. Pickens MK, Yan JS, Ng RK, Ogata H, Grenert JP, Beysen C, Turner SM, 
Maher JJ: Dietary sucrose is essential to the development of liver injury 
in the MCD model of steatohepatitis.  J Lipid Res 2009, 50:2072-2082.
153. Rinella ME, Elias MS, Smolak RR, Fu T, Borensztajn J, Green RM: 
Mechanisms of hepatic steatosis in mice fed a lipogenic methionine 
choline-deficient diet.  J Lipid Res 2008, 49:1068-1076.
154. Yao ZM, Vance DE: The active synthesis of phosphatidylcholine is 
required for very low density lipoprotein secretion from rat 
hepatocytes.  J Biol Chem 1988, 263:2998-3004.
155. Pawar A, Botolin D, Mangelsdorf DJ, Jump DB: The role of liver × 
receptor-alpha in the fatty acid regulation of hepatic gene expression.  
J Biol Chem 2003, 278:40736-40743.
156. Basciano H, Miller A, Baker C, Naples M, Adeli K: LXRalpha activation 
perturbs hepatic insulin signaling and stimulates production of 
apolipoprotein B-containing lipoproteins.  Am J Physiol Gastrointest Liver 
Physiol 2009, 297:G323-G332.
157. Huang W, Dedousis N, Bandi A, Lopaschuk GD, O'Doherty RM: Liver 
triglyceride secretion and lipid oxidative metabolism are rapidly 
altered by leptin in vivo.  Endocrinology 2006, 147:1480-1487.
158. Huang W, Dedousis N, O'Doherty RM: Hepatic steatosis and plasma 
dyslipidemia induced by a high-sucrose diet are corrected by an acute 
leptin infusion.  J Appl Physiol 2007, 102:2260-2265.
159. Huang W, Dedousis N, Bhatt BA, O'Doherty RM: Impaired activation of 
phosphatidylinositol 3-kinase by leptin is a novel mechanism of 
hepatic leptin resistance in diet-induced obesity.  J Biol Chem 2004, 
279:21695-21700.
160. Huang W, Metlakunta A, Dedousis N, Ortmeyer HK, Stefanovic-Racic M, 
O'Doherty RM: Leptin augments the acute suppressive effects of insulin 
on hepatic very low-density lipoprotein production in rats.  
Endocrinology 2009, 150:2169-2174.
161. Chirieac DV, Collins HL, Cianci J, Sparks JD, Sparks CE: Altered triglyceride-
rich lipoprotein production in Zucker diabetic fatty rats.  Am J Physiol 
Endocrinol Metab 2004, 287:E42-E49.
162. Taghibiglou C, Carpentier A, Van Iderstine SC, Chen B, Rudy D, Aiton A, 
Lewis GF, Adeli K: Mechanisms of hepatic very low density lipoprotein 
overproduction in insulin resistance. Evidence for enhanced 
lipoprotein assembly, reduced intracellular ApoB degradation, and 
increased microsomal triglyceride transfer protein in a fructose-fed 
hamster model.  J Biol Chem 2000, 275:8416-8425.
163. Benoist F, Grand-Perret T: Co-translational degradation of 
apolipoprotein B100 by the proteasome is prevented by microsomal 
triglyceride transfer protein. Synchronized translation studies on 
HepG2 cells treated with an inhibitor of microsomal triglyceride 
transfer protein.  J Biol Chem 1997, 272:20435-20442.
164. Fisher EA, Zhou M, Mitchell DM, Wu X, Omura S, Wang H, Goldberg AL, 
Ginsberg HN: The degradation of apolipoprotein B100 is mediated by 
the ubiquitin-proteasome pathway and involves heat shock protein 
70.  J Biol Chem 1997, 272:20427-20434.
165. Liao W, Yeung SC, Chan L: Proteasome-mediated degradation of 
apolipoprotein B targets both nascent peptides cotranslationally 
before translocation and full-length apolipoprotein B after 
translocation into the endoplasmic reticulum.  J Biol Chem 1998, 
273:27225-27230.
166. Ginsberg HN: Role of lipid synthesis, chaperone proteins and 
proteasomes in the assembly and secretion of apoprotein B-
containing lipoproteins from cultured liver cells.  Clin Exp Pharmacol 
Physiol 1997, 24:A29-A32.
167. Ginsberg HN, Fisher EA: The ever-expanding role of degradation in the 
regulation of apolipoprotein B metabolism.  J Lipid Res 2009, 
50(Suppl):S162-S166.
168. Shelness GS, Ingram MF, Huang XF, DeLozier JA: Apolipoprotein B in the 
rough endoplasmic reticulum: translation, translocation and the 
initiation of lipoprotein assembly.  J Nutr 1999, 129:456S-462S.
169. Yao Z, Tran K, McLeod RS: Intracellular degradation of newly synthesized 
apolipoprotein B.  J Lipid Res 1997, 38:1937-1953.
170. Mortimore GE, Miotto G, Venerando R, Kadowaki M: Autophagy.  Subcell 
Biochem 1996, 27:93-135.
171. Seglen PO, Berg TO, Blankson H, Fengsrud M, Holen I, Stromhaug PE: 
Structural aspects of autophagy.  Adv Exp Med Biol 1996, 389:103-111.
172. Cuervo AM: Autophagy: many paths to the same end.  Mol Cell Biochem 
2004, 263:55-72.
173. Ohsaki Y, Cheng J, Fujita A, Tokumoto T, Fujimoto T: Cytoplasmic lipid 
droplets are sites of convergence of proteasomal and autophagic 
degradation of apolipoprotein B.  Mol Biol Cell 2006, 17:2674-2683.
doi: 10.1186/1743-7075-7-35
Cite this article as: Sundaram and Yao, Recent progress in understanding 
protein and lipid factors affecting hepatic VLDL assembly and secretion 
Nutrition & Metabolism 2010, 7:35